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1. Introduction
Antony van Leeuwenhoek’s observation of “animalcules” in the tarter of teeth in 1683 marked
the beginning of humans trying to understand their relationship with microbes. Now com‐
monly referred to as “bacteria” or the “microbiota”, we share our inner and outer space with
these single-celled organisms. They are present all around us in the oceans, soil, leaves, and
even air [1]. One of the microbial niches that has recently garnered much attention is the human
body. In this niche, we share the table with 1014 microbial cells, which outnumber our eukary‐
otic cells ten to one [1, 2]. These organisms colonize most body sites, including the skin, oral
cavity, gastrointestinal, urogenital and respiratory tracts. Additionally, there is 150 times more
genetic material associated with our resident bacteria when compared to our own DNA and
comprise what is known as our body’s “second genome,” a concept recently reviewed by Zhu
et al. [3]. In an effort to understand the role that these organisms have on human development,
health and disease, the National Institutes of Health launched the “Human Microbiome
Project” in 2007 in an effort to elucidate this host-microbe interaction [4-6].
The role of bacteria is most obvious in the gastrointestinal tract (GIT). Bacteria in this niche
have the ability to break down substances that otherwise could not be digested by GIT cells;
they also produce metabolites needed by the body such as vitamin K (menaquinones), folate,
B12, and riboflavin [7-12]. The GIT has a surface area the size of a tennis court and is home to
1011-1012 organisms per gram of colonic content [1, 13]. The predominant bacterial phyla present
in the GIT include the Firmicutes and Bacteroidetes with low levels of Proteobacteria, Actino‐
bacteria, Fusobacteria, and Verrucomicrobia [14-16]. It has been noted that members of the
predominant factions (the Firmicutes and Bacteroidetes) belong to only three groups,
Bacteroides, Clostridium coccoides (cluster XIVa) and Clostridium leptum (cluster IV) [15, 17, 18].
© 2012 Overstreet et al.; licensee InTech. This is an open access article distributed under the terms of the
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There are also Archaea present in the GIT and have been found to belong to one phylotype,
Methanobrevibacter smithii [14, 19].
1.1. Initial colonization of the gastrointestinal tract
Infants are born sterile and establishment of the GI microbiota begins shortly thereafter.
Studies in mice have revealed that the first organisms to colonize include lactobacilli,fFlavo‐
bacteria and Group N Streptococci [20]. These three groups were found in the stomach and
the small and large intestine. When the mice were 12 days of age, the flavobacteria disappeared
from all three sites. Concurrently, there was a rapid increase in the presence of enterococci and
slow lactose fermenting coliform bacilli reaching 109 bacteria per gram of tissue in the large
intestine. This spike was transient however, and as the mice aged, a shift toward a more strict
anaerobic population occurred in the large intestine. This ordered colonization occurs because
aerotolerant organisms are able to colonize the GIT early in the presence of oxygen. Through
their metabolism, they reduce the redox potential and allow for the later colonization and
replication of strict anaerobes [21].
1.2. Impact of the method of delivery on colonization
In humans, the method of delivery impacts the initial microbiota of the infant [22-24]. In a
study of Venezuelan women, vaginal delivery was associated with initial colonization by
Lactobacillus, Prevotella, Atopobium, and Sneathia spp.; in contrast Cesarean delivery was
associated with colonization of Staphylococcus, Propionibacterium, and Corynebacterium spp.
(organisms typically found on skin). It was also noted that the initial bacteria present in infants
born vaginally were vertically transferred from the mother. This was not the case for those
born via Cesarean. A Finnish study analyzed infant fecal samples collected between three days
of age and six months of age to evaluate temporal colonization [23]. The results revealed that
at three days of age, all but one infant, regardless of the delivery method, were colonized with
aerobic bacteria. However, a higher percentage of vaginally delivered infants were colonized
with Bifidobacterium-like (BLB) and Lactobacillus-like (LBB) bacteria as compared to Cesarean
delivered infants. These differential colonization patterns were corrected by day ten for LBB
and by day 30 for BLB. Additional characterization of the fecal microbiota revealed that at one
month of age, infants born via Cesarean had a significant increase in Clostridium perfringens
(25% to 56%); an increase not seen in vaginally delivered infants. This is an important obser‐
vation, as C. perfringens has been thought to play a role in sudden infant death syndrome (SIDS)
[25]. Also of note, significant differences in the levels of Bacteroides fragilis were observed
between the two methods of delivery [23]. Specifically, this bacterium was present at statisti‐
cally higher numbers in vaginally delivered infants as compared to Cesarean delivered infants
at all time points throughout the six months of the study.
These differences in initial colonizers have been associated with adverse effects, as infants born
via Cesarean are more susceptible to skin infections with methicillin resistant Staphylococcus
aureus (MRSA). A 2004 report indicated that 82% of infant MRSA cases in Chicago and 64% in
Los Angeles were delivered via Cesarean , all of which involved healthy, full-term infants [26].
An additional prospective cohort study indicated a link between Cesarean delivery and
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Clostridium difficile infection, which was further associated with the development of wheeze,
asthma, eczema, and food allergies throughout the first seven years of life [27]. Consistent with
these findings, a Norwegian study documented an association between asthma and Cesarean
delivered children [28]. Although the epidemiological connections between Cesarean delivery,
the composition of the microbiota, and disease are still being studied, strong evidence exists
that early colonization of the intestines with aerobic skin microbes is associated with health
risks.
1.3. Impact of feeding method on colonization
Another factor affecting early colonization of the human gut is determined by feeding method
[29]. In one study of vaginally delivered infants, the fecal microbiota of breast-fed compared
to formula-fed infants within the first month of life was analyzed using fluorescence in situ
hybridization (FISH) to evaluate 11 separate groups of organisms [29]. Bifidobacterium spp.
were the most prominent organisms found to colonize infants fed breast milk, comprising 69%
of the bacterial population, with the next most prevalent group being the Bacteroides and
Prevotella spp. making up 12%. With respect to the fecal microbiota of formula-fed infants, the
microbiota was actually more diverse than that found in the breast-fed babies. Formula-fed
infants had Bifidobacterium spp. as the most predominant group, however, they only comprised
32% of the bacterial population while Bacteroides and Prevotella spp. comprised 29% of the
composition. Additionally, Atopbium spp. were found to account for 8% of the microbiota in
formula-fed infants, but only comprised 1% of the community in the breast-fed infants.
1.4. Microbial changes that occur after weaning
The next major shift in the microbial population occurs during weaning. In a study consisting
of infants from five European countries, the composition of the fecal microbiota at four weeks
post-weaning was analyzed via FISH using 10 different probes [30]. When considering the
results from all of the infants, it was noted that the microbial communities consisted primarily
of Bifidobacterium (37%), C. coccoides (14%) and Bacteroides (14%). When samples were obtained
from infants that were separated by geographic location, differences among the groups were
noticeable. Infants from Spain had significantly greater Lactobacillus spp. and less Bifidobacte‐
rium spp. as compared to infants from the UK, Sweden, Germany, and Italy. The Spanish fecal
samples also had significantly greater presence of Bacteroides spp. and C. leptum compared to
those from the UK, Sweden, or Italy. The numbers of C. leptum was highest in samples obtained
from German infants. The microbiota of infants from Spain also had significantly greater
amounts of enterobacteria when compared to those from the UK, Sweden, or Germany, and
higher numbers of Streptococcus spp. compared to those from Germany. The infants with the
highest amount of Bifidobacterium spp. were from Sweden and the UK. Further separation of
the data revealed that breast-fed infants had an increased percentage of Bifidobacterium spp.
while Bacteroides spp. and C. coccoides were reduced post-weaning. Additionally, delivery
method also influenced the microbiota composition, with vaginally delivered infants having
higher numbers of Bacteroides present.
The Role of the Microbiota in Gastrointestinal Health and Disease
http://dx.doi.org/10.5772/53920
3
This study also reported results from infants who provided samples before (at six weeks
of  age)  and  four  weeks  after  weaning  [30].  Switching  to  solid  food  during  this  time
caused a significant reduction in the presence of bifidobactera, enterobacteria, and C. diffi‐
cile/C. perfringens  proportions. These reductions were accompanied by significant increas‐
es in both C. leptum and C. coccoides clusters. Again, location also played a significant role
in the microbial differences at weaning. Spanish infants had the greatest increase in both
C. coccoides and C. leptum post-weaning compared to the other four countries, while enter‐
obacteria was significantly decreased in the Spanish samples compared to those from the
other  countries.  The samples from Spanish infants  also had significant  increases in Ato‐
pobium  spp.  compared to  those from Sweden and Germany and Streptococcus  spp.  com‐
pared to Germany and Italy.  The authors also report  significant decreases post-weaning
in the enterobacteria present in the Italian infant samples as compared to samples from
Sweden  and  the  UK.  As  mentioned  previously,  feeding  and  delivery  method  alter  the
composition  of  the  microbiota  at  birth;  this  is  also  true  after  weaning.  Formula-fed  in‐
fants  had  higher  proportions  of  C.  leptum  in  their  feces  compared  to  breast-fed  infants
post-weaning. Infants born via Cesarean section possessed increased levels of Bacteroides
spp. after weaning, whereas there was no change in the abundance of this group in vagi‐
nally delivered infants. Additionally, Atopobium spp. decreased in vaginally delivered chil‐
dren but increased in Cesarean delivered children post-weaning [30].
Studies describing development or maturation of the human microbiota reveal that as an
individual ages, the microbiota shifts from predominantly facultative anaerobes to strict
anaerobes, just as previously observed in rodents [20]. Notably, variations in initial coloniza‐
tion associated with different delivery and feeding methods seems to profoundly impact the
microbial community post-weaning. Additionally, geographic location plays an important
role in the initial colonization of the (GIT). In spite of all these variables, several themes for
colonization can be described. Initially, Bifidobacterium spp. are the primary colonizers of the
infant GIT along with other species such as Bacteroides, Lactobacillus, Prevotella, and Atopobi‐
um. As the infant matures, the oxygen presence in the gut is reduced and the infant begins
eating solid food, which promotes a transition towards the growth and maintenance of the
anaerobes found in the C. coccoides and C. leptum clusters.
1.5. The microbiota and gastrointestinal homeostasis
The commensal microbiota has a tremendous influence on the development and functional
capabilities of the GIT of its host. Numerous studies have documented the effects that the
microbiota has on GIT development in mice. Specifically, the morphology of the intestines
differs significantly in animals devoid of microbes (i.e., germfree) compared to conventionally-
reared (CONVR) mice [31]. The mucus layer is thinner and epithelial cells have a slower rate
of turnover compared to those from conventional animals, primarily because of extended time
in the S and G1 phases of the cell cycle [32]. This can be corrected by bacterial colonization. In
Figure 1, panel A shows intestinal tissue from germfree (GF) mice and panel B shows tissue
from a mouse colonized with Brachyspira hyodysenteriae. Colonization with B. hyodysenteriae
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elicits the production of goblet cells and increases the heights of the mucosa, resembling what
is seen in CONVR mice.
 
(a) (b) 
Figure 1. Photomicrographs of cecal tissue from a) a germfree mouse and b) a mouse monoassociated with Brachy‐
spira hyodysenteriae. Note the changes in the cellularity, presence of goblet cells, and height of the mucosa in the ceca
from the monoassociated mouse 28 days after colonization with B. hyodysenteriae.
In the small intestine, this change in epithelial cell transit time is doubled, going from 53 hours
in a CONVR mouse to 115 hours in a GF mouse [33]. The most noticeable gross change in GF
mice is the enlargement of the cecum, which can comprise up to 19% of the mouse’s body
weight [34]. The cecum of a GF mouse can assume a more normal size (4.5% body weight)
following colonization with a mixture of Lactobacillus spp., Group N streptococci , Bacteroides
spp., enterococci and coliform bacilli recovered from CONVR mice [34]. As shown in Figure
2, monoassociation with B. hyodysenteriae also returns the cecum to a more normal size.
Of interest, not all bacteria tested were able to return the cecum to a normal size. It was noted
that colonizing mice with Lactobacillus spp. and Group N streptococci only was not sufficient
to change the morphology of the cecum. However, when Bacteroides spp. colonized the mice,
the morphology assumed a more normal size. Other differences between GF and CONVR mice
include the consistency of the cecal contents, with the contents from a GF mouse being more
liquid, hypotonic and alkaline than in a CONVR mouse [35]. Additionally, GI transit time is
slower in GF mice, which are also prone to vitamin deficiency due to a lack of bacterial
metabolism [36-38]. In GF rats, monoassociation with either a rat-derived Escherichia coli strain
or a sarcina-like micrococcus was able to reverse the vitamin K deficiency. Research identifying
the response to Salmonella enteritis serovar Typhimurium challenge indicated that there was a
50-fold greater translocation of bacteria to the mesenteric lymph node, and organisms were
present in the blood of GF mice, something not seen in CONVR mice [37]. This phenomenon
occurred due to the decreased transit time in the small intestine of GF mice, thereby allowing
the Salmonella to multiply in the host and translocate to other tissue sites.
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Figure 2. Physical and morphological changes associated with microbial colonization. Shown here are ceca from a
germfree mouse (left), monoassociated mouse (center), and conventional microbiota mouse (right). Note the in‐
creased size of the cecum from the GF mouse. The distal end of the cecum (appendix) of the monoassociated mouse
has begun to undergo morphological changes, including the development of a lymphoid tissue known as a cecal ton‐
sil.
1.6. Effect of bacterial colonization on immune development
In addition to its importance in maintaining gut homeostasis, the GI microbiota is also critical
for normal priming and development of the immune system [39-41]. GF mice have reduced
numbers of immune cells present in the lamina propria and have smaller Peyer’s patches
compared to CONVR mice. They also have a diminished capacity for antibody production,
fewer plasma cells, smaller mesenteric lymph nodes, and reduced numbers of germinal centers
compared to CONVR mice [39]. However, this underdeveloped immune system is fully
capable of mounting a response comparable to that of a CONVR mouse when stimulated with
bacterial antigen or protein [40, 41]. Macrophages from CONVR mice process antigen faster
than those from GF mice, likely because the continued exposure of CONVR macrophages to
bacterial antigen allows them to be “primed” for antigen degradation; a phenomenon that does
not occur in GF mice [41]. The presence of bacteria in the GIT promotes decreased immunor‐
eactivity towards commensal organisms. The barrier between the gut microbiota and the
underlying gastrointestinal associated lymphoid tissue consists of a single layer of epithelial
cells covered by two layers of mucus [42, 43]. The inner layer of mucus is approximately 100
μm thick while the outer layer is approximately 700 μm in the rat colon [43]. The inner layer
is firmly attached to the epithelial cells and devoid of bacteria, while the outer layer is
“loose”and contains commensal organisms [44]. The major constituent of these layers is a
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protein known as Muc2 [42]. The importance of Muc2 has been highlighted by the development
of Muc2-/- mice. These mice fail to gain weight, have diarrhea by seven weeks of age, occult
blood present in their feces by eight weeks of age, and the majority of mice had gross bleeding
and reversible rectal prolapse by nine weeks of age [45]. These mice also develop microscopic
evidence of colitis as early as five weeks of age.
Underneath the mucus layers lay the intestinal epithelial cells, which are held together by tight
junction proteins such as occludins, claudins, and junctional adhesion molecules [46]. These
proteins seal the paracellular junction between the cells and regulate the entry of nutrients,
ions and water. They also act as a barrier against bacterial entry. Loss of epithelial barrier
function promotes a break in immunological tolerance and facilitates immunoreactivity
towards the normal commensal microbiota (Figure 3). This phenomenon has been demon‐
strated in mouse studies employing 2,4,6 trinitrobenzensulfonic acid (TNBS), a chemical that
disrupts the epithelial barrier to allow translocation of bacteria, resulting in the induction of
both innate inflammatory responses and antigen-specific immune responses [47]. Subsequent
to the loss of epithelial barrier function, these mice develop severe gastrointestinal inflamma‐
tion, which can be ameliorated by pretreating with antibiotics to reduce the microbial load [47].
The role of the commensal bacteria in regulating the immune response was elegantly demon‐
strated in a study by Wlodarska et al. [48]. Mice administered metronidazole were more
susceptible to subsequent infection with the pathogen, Citrobacter rodentium. Metronidazole-
treated mice had increased submucosal edema, ulcerations, mucosal hyperplasia and de‐
creased numbers of goblet cells. The author also noted enhanced expression of IL-25 and Reg3γ
mRNA and an increased presence of NK cells and macrophages in the lamina propria of these
mice, indicating an increase in microbial stimulation. The inner mucous layer of metronida‐
zole-treated mice was significantly thinner and mRNA expression of genes encoding for the
goblet-cell specific proteins Muc2, TFF3, and RelmB was also decreased in these mice [49, 50].
The thinning of the inner mucous layer following metronidazole treatment allowed for C.
rodentium to more closely associate with the epithelium and promote production of the pro-
inflammatory cytokines and chemokines TNF-α, IFN-γ, and MCP-1. This study highlights the
contribution of the commensal microbiota in the production of the mucus barrier and subse‐
quently in maintaining mucosal homeostasis [48].
It has also been noted that specific members of the resident microbiota are able to illicit specific
immune functions. Colonization with Bacteroides fragilis expressing polysaccharide A (PSA)
suppressed development of T helper 17 (Th17) CD4+ T cells by promoting the development of
Foxp3+ T regulatory (Treg) CD4+ T cells and inducing IL-10 expression via TLR2 signaling [51].
Additional studies have demonstrated that purified PSA is sufficient to expand the numbers
of Foxp3+ Treg cells [52]. B. fragilis inhabits colonic crypts. This niche puts the organism in close
contact with the immune system but its production of PSA ensures that no inflammatory
response is induced. Both prophylactic and therapeutic treatment of mice with PSA has been
shown to ameliorate TNBS-induced colitis in mice [52]. More recently, work from Atarashi et
al., eloquently demonstrated a role for indigenous Clostridium species in the induction of
colonic Treg cells [53]. Colonization of GF mice with a cocktail of 46 Clostridium strains enriched
for clusters IV and XIVa promoted TGF-β production from intestinal epithelial cells and
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increased the number of Foxp3+ Treg cells in the colon. Furthermore, inoculation of young
CONVR mice with Clostridium species facilitated resistance to both dextran sodium sulfate
(DSS)- and oxazolone-induced colitis as well as increased systemic Immunoglobuin E (IgE)
production as adults.
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Figure 3. Panel A shows normal mucosal homeostasis. The epithelial cells provide a barrier between the commensal
bacteria and the underlying immune cells. Panel B depicts acute inflammation. The epithelial cell barrier has been
breached, allowing bacteria to be readily detected by the immune system and promote a pro-inflammatory immune
response.
The segmented filamentous bacteria  (SFB)  is  another  microorganism of  interest  that  has
been implicated in the induction of Th17 responses [54]. Ivanov et al. found that C57BL/6
mice purchased from the Jackson Laboratory had significantly less IL-17-producing CD4+
T cells  in  the  small  intestine  compared  to  those  from Taconic  Farms.  This  discrepancy
could  be  corrected  via  intragastric  gavage  of  the  Jackson  mice  with  contents  from  the
small intestines of the Taconic mice. Using a 16S ribosomal RNA PhyloChip analysis, SFB
were identified in the microbiota of mice from Taconic Farms but not in those from the
Jackson  Laboratory.  Monoassociation  of  mice  with  SFB induced the  production  of  Th17
cells  and  up-regulated  genes  encoding  antimicrobial  peptides  and  serum  amyloid  A
(SAA).  SAA co-cultured  with  naive  CD4+  T  cells  and  lamina  propria  derived  dendritic
cells  induced  Th17  cell  differentiation  in  vitro.  The  authors  concluded  that  SFB,  which
tightly adheres to and imbeds itself among the microvilli on the epithelial cell surface, in‐
duces the production of SAA by intestinal epithelial cells. In turn, the SAA acts on lami‐
na propria dendritic cells to stimulate the induction of Th17 cells.  Colonization with SFB
has  also  been  shown  to  protect  against  C.  rodentium  infection.  Th17  cytokines  such  as
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IL-22  likely  stimulate  intestinal  epithelial  cells  to  secrete  antimicrobial  peptides  to  limit
the growth of the pathogen and its infiltration into the colonic wall [54].
1.7. Effect of bacterial colonization on other aspects of the body
In  addition  to  promoting  immune  maturation,  the  commensal  microbiota  also  helps  to
regulate  fat  storage.  GF mice  eat  29% more  food than conventional  mice  yet  have 42%
less body fat and a decreased metabolic rate [55]. Colonization of GF mice with cecal con‐
tents from conventional mice for 14 days caused a 57% increase in total body fat with a
concomitant  27%  reduction  in  food  intake.  These  “conventionalized”  mice  also  had  in‐
creases in leptin, fasting glucose, and insulin levels compared to GF mice; they also devel‐
oped insulin  resistance.  Levels  of  mRNA specific  for  the  transcription  factors,  SREBP-1
and ChREBP,  were also elevated leading to  increased production of  lipogenic  enzymes.
Fat formation is aided by the regulator lipoprotein lipase (LPL) and is inhibited by the fiaf
gene  product  whose  expression  is  suppressed  in  microbiota-bearing  conventional  mice.
The authors  suggest  that  the bacteria  in  the gut  breakdown dietary polysaccharide into
monosaccharaides  that  are  then  transported  to  the  liver  to  activate  lipogenic  enzymes.
This  process promotes fat  formation in the peripheral  tissues due to the suppression of
fiaf. In addition to the production of white adipose tissue, the microbiota may also play a
role in eye health [56]. A recent study revealed differences in the lipid profiles in the lens
and retinas  of  GF mice  as  compared to  CONVR mice.  The  CONVR mice  had reduced
concentrations of multiple phosphatidylcholines and an overall reduced presence of phos‐
pholipids in the lens.  The authors postulate these changes may be due to the increased
exposure  of  the  CONVR mice  to  more  oxidative  stress  than their  GF counterparts  [56].
Together,  these  studies  help us  realize  the  effects  that  the  gut  microbiota  may have on
host systems that, at the surface, seem to have limited or no connection to the GIT.
1.8. Bacterial production of short chain fatty acids
Another health benefit that the microbiota provides its host revolves around the produc‐
tion  of  short-chain  fatty  acids  (SCFA)  such  as  acetate,  propionate,  and butyrate  as  end
products of anaerobic fermentation [57]. These SCFA (predominantly butyrate) can be uti‐
lized as energy sources by eukaryotic cells.  Members of the Clostridium  clusters IV (e.g.,
Faecalibacterium prausnitzii)  and XIVa (e.g.,  Roseburia  spp. and Eubacterium rectale)  are the
primary butyrate producers in the GIT, and they comprise approximately 2-15% of the to‐
tal gut microbiota [14, 58-61].  Butyrate, a four-carbon fatty acid, is produced by bacteria
via one of two metabolic pathways. The first pathway utilizes the enzymes phosphotrans‐
butyrylase and butyrate kinase to form butyrate from butyryl-CoA to yield one ATP per
one  molecule  of  butyrate  produced [62,  63].  The  second pathway,  which  is  utilized  by
most  organisms  in  the  gut,  uses  butyryl-CoA acetate  CoA transferase  to  form butyrate
and acetyl-CoA from butyryl-CoA [64, 65].
Once produced, butyrate has multiple effects on gut health. A primary use is as a prefer‐
red energy source for colonocytes,  and the mechanisms by which butyrate is utilized in
the GIT is summarized in Figure 4 [66-69]. Two biomarkers of energy homeostasis, ATP
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and NADH/NAD+  levels, are both significantly reduced in only the colonic tissues of GF
mice as compared to CONVR mice [70].  This observation indicates that GF mice have a
reduction in TCA cycle activity, and subsequently less ATP is generated for cellular ener‐
gy.  Moreover,  this  reduction  in  ATP  was  correlated  with  increased  signs  of  energetic
stress in colonocytes, including increased expression of 5’-adenosine monophosphate-acti‐
vated  protein  kinase  (AMPK).  Consistent  with  previous  reports  describing  a  role  for
AMPK in  inducing autophagy [71],  GF coloncytes  also  expressed elevated levels  of  the
autophagosome marker LC3-11. Transmission election microscopic analysis revealed that
significantly  more  GF  colonocytes  were  undergoing  autophagy  than  colonocytes  from
CONVR mice. Colonizing GF mice with a conventional microbiota reversed these effects,
as did incubation of isolated colonocytes with butyrate.  Additional experiments employ‐
ing  the  fatty-acid  oxidation  blocker,  etomoxir,  demonstrated  that  colonocytes  consume
butyrate as an energy source and not as a histone deacetylase (HDAC) inhibitor, another
known function of butyrate [72, 73].
Butyrate functions as an HDAC inhibitor by blocking cellular deacetylase activity and al‐
lowing histone acetylation [72,  73].  Histone modification causes changes in cellular gene
expression patterns; compounds and molecules that can elicit these modifications are be‐
ing  studied  as  potential  anti-cancer  therapeutics  [74].  A  comparative  study  of  gene  ex‐
pression patterns in HT-29 cells (a colon carcinoma-derived cell line), treated with either
butyrate  or  trichostain A (a  known HDAC inhibitor)  revealed that  both substances  had
similar effects on gene expression [75]. Upregulated genes (21 total) were found to regu‐
late the cell  cycle,  signal transduction,  DNA repair and genome transcription.  Only two
genes  were  down-regulated—lactoferrinδ  and  MAPKAP  kinase.  It  is  also  important  to
note that both butyrate and trichostain A inhibited the growth of HT-29 cells by creating
an arrest in the G1  phase of the cell  cycle [76].  Butyrate may also down-regulate pro-in‐
flammatory responses via its HDAC activity, as incubation of butyrate with inflamed bi‐
opsy samples  or  LPS-induced peripheral  blood mononuclear  cells  (PBMCs)  reduced the
mRNA expression of IL-6, TNF-α, TNF-β, and IL-1β [77]. Additionally, in murine studies
of TNBS- and DSS-induced colitis,  and in ulcerative colitis  (UC) patients,  administration
of butyrate enemas ameliorates disease activity via NFκB inhibition [77-79]. Butyrate has
been shown to decrease both COX-2 and PGE2 expression in HT-29 cells stimulated with
TNF-α [80].
The information presented in this section clearly defines a central role for the gut micro‐
biota in many physiological processes;  the microbiota even has a tremendous impact on
the host’s  health status.  Causal  links likely exist  between the methods by which infants
are  delivered,  their  gut  microbial  colonization patterns  and subsequent  health  concerns,
including  asthma,  eczema  and,  food  allergies.  Associations  between  gut  bacterial  com‐
munities  and  obesity,  diabetes,  and  cardiovascular  disease  have  also  been  documented
[81-83].  A significant body of literature also links changes in the composition of the gut
microbiota  with  inflammatory  bowel  disease  (IBD),  which  is  discussed  in  detail  in  the
following section [84-89].
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Figure 4. Microbial regulation of colonocyte metabolism. Schematic depicting how dietary fiber is fermented by
microbes into butyrate in the lumen of the colon, which is then transported into the colonocyte. In the colonocyte,
butyrate promotes oxidative metabolism and inhibits autophagy. Based on transcriptome and proteome experiments,
enzymes regulated by microbes are shown in boxes. In all cases, boxed enzymes that function in β-oxidation and the
TCA cycle are downregulated in GF colonocytes, revealing that microbes positively regulate their expression. Diminish‐
ed ATP results in phosphorylation of AMPK and p27, which culminates in autophagy. (Cell Metab. 2011 May 4;13(5):
517-5) Reprinted with permission from the publisher license number 2977121495018
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2. Introduction to inflammatory bowel disease
In 1932, three physicians, Burrill Crohn, Leon Ginzburg, and Gordon Oppenheimer described
a disease of unknown etiology in the terminal ileum of young adults [90]. The disease was
characterized as being similar to UC (fever, diarrhea and weight loss) and having ulcerations
of the mucosa that would eventually lead to stenosis of the lumen and formation of multiple
fistulas. Eventually, surgical intervention was used to resect the affected portion of the
intestinal tract and patients recovered with little signs of the disease persisting. In their 1932
report, Crohn and colleagues discuss observations from other physicians regarding observa‐
tions of granulomas in the small and large intestine of unknown etiology being classified under
the umbrella term “benign granulomas”. Still today Crohn’s disease (CD) and UC are both
included under the umbrella term “inflammatory bowel disease.” Crohn and colleagues
described the disease as beginning at the ileocecal junction with lesions separated by normal
mucosa [90]. They described inflammation of the submucosa and the muscularis resulting in
a markedly thickened bowel wall. The presence of “giant cells” was also noted, which they
attributed to vegetable matter becoming entrapped in the ulcers and become encapsulated
during healing. The authors concluded that the presence of these giant cells in the granulom‐
atous lesion led others to believe that the inflammation was due to an unusual form of
tuberculosis. However, the authors could not find any evidence of tuberculosis in their 14
patients.
Clinically, the patients with IBD were characterized as young adults with fever, diarrhea, dull
abdominal pain, and vomiting; they were also weak, anemic and had poor appetite. Upon
physical examination, the author noted five commonalties: 1) a mass in the right iliac region,
2) evidence of fistula formation, 3) emaciation and anemia, 4) approximately half of the subjects
had undergone an appendectomy, and 5) evidence of intestinal obstruction. Treatment was
supportive and surgical resection of the affected portion of the intestinal tract was recom‐
mended; 13 of their 14 patients had no symptoms post-operatively. For the one patient that
developed recurrent symptoms, it was later determined that not all of the affected intestinal
tissue had been resected during the first surgery.
Eighty years after the first published article of what would become known as “Crohn’s
disease,” there is still no cure for this disease nor do we fully understand its etiology. Un‐
fortunately, the number of people being diagnosed with IBD is increasing yearly [91]. There
is not one specific, causative agent of IBD; instead the etiology is thought to be multifactorial
in nature, with host genetics, environmental factors, the induction of aberrant immune
responses, and the gastrointestinal microbiota all contributing to disease pathogenesis.
2.1. Genetic factors affecting IBD
As of 2011, genome-wide meta-analyses had identified 71 susceptibility loci associated with
CD, 47 with UC and 28 associated with both, some of which are shown in Figure 5 [92-95].
Here, we focus on genetic variants within specific genes involved in mediating host responses
to microbial components.
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Figure 5. Inflammatory bowel disease susceptibility loci. The loci (depicted by lead gene name) attaining genome
wide significance (p < 5x10-8) are shown for Crohn’s disease (CD, red), ulcerative colitis (UC, blue) and IBD (black where
p < 5x10-8 in CD and UC; red were p < 5x10-8 in CD and p < 5x10-4 in UC; blue where p < 5x10-8 in UC and p < 5x10-4 in
CD. Reprinted with permission from the publisher license number: 2977121069437
2.1.1. Nod2
One of the first candidate genes linked to IBD susceptibility was Nod2. Located on chromosome
16, the defective allele affects the activation of the transcription factor NF-κB. NOD2 is
expressed in antigen-presenting cells, macrophages, lymphocytes, ileal Paneth cells, and
intestinal epithelial cells and functions as an intracellular microbial recognition molecule
[96-100]. NOD2 senses muramyl dipeptide (MDP), a minimally bioactive motif of peptido‐
glycan from both Gram-negative and Gram-positive bacteria. Once activated by its ligand,
NOD2 undergoes a conformational change to expose its CARD domains and recruits the kinase
RIP2 to the complex which associates with NOD2 via homophillic CARD-CARD interactions
[97]. This process leads to the activation of IKK and the subsequent degradation of IκB and
ultimately results in the translocation of NF-κB to the nucleus [96, 101].
Petnicki-Ocwieja et al. demonstrated that MDP stimulation of ileal crypts induced bactericidal
secretions capable of killing E. coli [102]. Moreover, the same authors showed that NOD2 was
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required for the bactericidal activity of crypt secretions of the terminal ileum. The composition
of the ileal microbiota of the NOD2-/- mice was significantly altered in comparison to their WT
counterparts. Specifically, NOD2-/- mice had increased numbers of Firmicutes, specifically
Bacillus species and Bacteroides species. Wild-type mice were able to clear an infection of
Helicobacter hepaticus, an opportunistic mouse pathogen, within seven days while NOD2-/- mice
remained colonized with H. hepaticus for at least 14 days post-infection [102]. Also of note, the
presence of a gut microbiota was required for the expression of NOD2. GF mice possessed
decreased levels of NOD2—a phenotype that could be reversed following monoassociation
with either Gram-negative or Gram-positive organisms. Together, these results outline a
reciprocal regulatory relationship between NOD2 expression and the gut microbiota.
2.1.2. ATG16L1
Another gene implicated in the pathogenesis of IBD that regulates cellular autophagy is
ATG16L1  [95,  103].  Autophagy  is  a  process  utilized  by  cells  to  recycle  cellular  compo‐
nents. This process may also be utilized by cells as a non-apoptotic method of program‐
med  cell  death  [104].  ATG16L1  is  expressed  by  CD4+  and  CD8+  T  cells,  CD19+  B  cells,
epithelial cells, and macrophages [105, 106]. Studies by Caldwell et al.  utilizing mice en‐
gineered to express low or hypomorphic levels of ATG16L1  revealed that this gene is in‐
deed  an  autophagy-related  protein.  Elevated  levels  of  cytosolic  proteins  normally
degraded by  a  rapamycin-induced degradation pathway were  found in  the  cells  of  the
ATG16L1 hypomorphic (ATG16L1HM) mice [95]. Additionally, cells from ATG16L1HM mice
possessed fewer autophagosomes following rapamycin treatment or nutrient deprivation.
The  small  intestines  and  colons  of  ATG16L1HM  mice  had  no  morphological  defects  in
crypt  height  or  villus  length  but  did  possess  abnormalities  found in  their  Paneth  cells.
Specifically, lysozyme within Paneth cells was found to be either depleted/absent or dif‐
fuse, which is in contrast to the normal and orderly packaging of lysozyme within gran‐
ules.  Decreased  levels  of  lysozyme  were  also  observed  in  the  ileal  mucus  layer  of
ATG16L1HM  mice.  However,  there were intact granules observed in the crypt lumen, in‐
dicating a potential role of ATG16L1 in the maintenance of the Paneth cell granule exocy‐
tosis  pathway.  The  authors  observed no differences  between WT and ATG16L1HM  mice
in terms of resistance to a challenge with Listeria monocytogenes. However, others have re‐
ported a reduction in intracellular  bacteria targeted to autophagic vacuoles following in
vitro infections of  HeLa or  Caco-2 cells  with S.  typhimurium  in  conjunction with siRNA
to reduce the expression of  ATG16L1  [105,  107].  Additional  work by Caldwell  et  al.  re‐
vealed  that  100  %  of  ileocolic  resection  specimens  obtained  from  humans  with  the
ATG16L1  risk allele had abnormal Paneth cells that looked similar to those found in the
ATG16L1HM mice [95].
Using siRNA to reduce ATG16L1 expression in THP-1 macrophages revealed an increase in
intracellular adherent and invasive E. coli (AIEC) as compared to normal THP-1 infected
macrophages [106]. AIEC promote enhanced production of TNF-α and IL-6 from macrophag‐
es. Silencing of ATG16L1 expression resulted in significant increases in both cytokines. The
authors postulate that bacterial clearance is less efficient in individuals with the risk alleles for
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ATG16L1. When AIEC are present, this reduction in bacterial clearance likely leads to increased
production of pro-inflammatory cytokines, which could tip the immune balance to an
inflammatory state. Thus, it appears that the presence of bacterial provocateurs (e.g., AIEC) in
the microbiota increases the risk of developing IBD in individuals possessing polymorphisms
in genes such as ATG16L or NOD2.
2.2. The immune response and IBD
The mucosal immune system is charged with the monumental task of balancing respon‐
siveness  and  tolerance  to  a  tremendous  number  of  environmental  antigens,  including
those from both food and bacteria. Although the exact cause of IBD remains elusive, sig‐
nificant evidence supports the hypothesis that GIT inflammation is initiated and perpetu‐
ated by a dysregulated immune response directed against the gut microbiota resulting in
deleterious  responses  in  genetically  susceptible  individuals  following  an  environmental
trigger.  The host with a genetic predisposition for IBD may possess defects in epithelial
permeability and/or altered regulation (i.e., NOD2 deficiency) of commensal bacteria. Po‐
tential  environmental  triggers  may include  smoking,  certain  medications,  or  a  gastroin‐
testinal  illness that induces a break in homeostasis.  Regardless of  the specific  genetic or
environmental trigger, what ensues is an exaggerated, inappropriate mucosal immune re‐
sponse characterized by chronic activation of T cells and the production of cytokines and
other inflammatory mediators.
The success of  cytokine-targeted immunotherapies for a subset of  IBD patients supports
the idea that these chemical messengers of the immune system play an important role in
disease  pathogenesis.  However,  the  nature  of  the  immune  phenotypes  observed  in  CD
and UC patients do differ [108]. The immune response of CD is typically associated with
a T helper 1 (Th1) phenotype while UC is characterized by a T helper 2 (Th2) phenotype
[108].  Isolated lamina propria  (LP)  CD4+  T  cells  from CD patients  produce IFN-γ when
stimulated via the CD2/CD28 pathway; in contrast, LP CD4+ T cells from UC patients se‐
creted mostly IL-5 [109]. Another cytokine with a strong link to CD is IL-12 [110]. Messen‐
ger RNA for IL-12p40 in LP mononuclear cells (LPMC) was found in 85 % of CD patients,
a percentage significantly higher than that found in healthy and UC GIT tissue samples.
Similarly,  IL-12p35 mRNA was detectable in the LPMC of 92 % of CD patients;  expres‐
sion was again significantly higher than for healthy and UC patients.  Elevated levels of
IL-12 were also detectable in the serum of CD patients [110], and this potent Th1-promot‐
ing cytokine is able to induce IFN-γ production from LP lymphocytes (LPL) isolated from
CD patients [111]. Additionally, studies employing a murine model of TNBS-induced col‐
itis have revealed that administration of anti-IL-12 antibodies ameliorated disease severi‐
ty, presumably by decreasing IFN-γ secretion from LP CD4+ T cells [112].
In UC, production of the cytokines IL-5 and IL-13 appear to mediate the disease process. Using
LPMC from IBD patients, those with UC had increased production of IL-13 and IL-5 upon in
vitro restimulation as compared to LPMCs recovered from either CD patients or healthy
individuals [113]. Levels of IFN-γ produced by LPMC from UC patients were similar to those
produced by cells from healthy controls. The authors specifically identified that CD4+ CD161+
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NK T cells were the primary source of IL-13 in UC patients, as these cells produced 30-fold
more IL-13 than NK T cells from CD patients following in vitro restimulation.
More recent work has implicated the T helper 17 (Th17) lineage of CD4+ T cells in the chronic
inflammation observed in IBD [114, 115]. The development of Th17 T cells is dependent upon
the presence of both IL-6 and TGF-β [115]. Colonic biopsies from UC and CD patients expressed
higher levels of IL-17A mRNA as compared to those from healthy controls [115-117]. Immu‐
nohistochemical analysis of these tissues identified increased numbers of IL-17A+ cells in both
the LP and the epithelium of UC and CD patients as compared to controls [116]. Additional
work also noted the presence of IL-17+ cells in patients with active IBD [114]. However, the
IL-17+ cells were found predominantly in the LP of UC patients but in the submucosa and
muscularis propria of CD patients [114]. These different locations of IL-17+ cells complements
prior observations that CD lesions often present as transmural while those in UC are superfi‐
cial. Also of note, a comparison of biopsies from patients with active versus inactive disease
revealed that IL-17+ cells were only increased in numbers during active disease. The authors
also determined that both T cells and monocytes/macrophages are a source of IL-17, and that
IBD patients have elevated levels of IL-17 in their sera as compared to undetectable levels of
this cytokine in the sera of healthy individuals.
The maintenance of Th17 T cells requires the presence of IL-23 [115]. Of interest, a gene variant
significantly associated with CD encodes for the IL-23R, which, along with IL-12Rβ1, com‐
prises the IL-23 receptor complex [118, 119]. This receptor complex interacts with IL-23 (a
heterodimer of IL-12p40 and IL-23p19) to direct the production of a TH17 immune response
[120-122]. Anti-IL-23 antibodies have been shown to both prevent and ameliorate established
disease in a T-cell transfer model of murine colitis [123]. Studies of human tissues demonstrate
that IL-23R expression is upregulated not only on IL-17 producing CD4+ T cells, but also on
IFN-γ+ T cells in both UC and CD patients [115]. Stimulation of LP CD4+ T cells from UC patients
with IL-23 significantly increased IL-17 production; in contrast, IL-23 stimulation of LP CD4+
T cells from CD patients resulted in enhanced IFN-γ secretion [115]. In addition to promoting
the production of TH17 cells, IL-23 also inhibits the production of Foxp3+ Treg cells [124] and
suppresses production of IL-10, a key regulatory cytokine [125].
Another important hallmark of the immune response observed in IBD is the production of IgG
antibodies against the normal commensal microbiota [126]. Increased intestinal permeability,
be it through genetic predisposition or environmental trigger, promotes enhanced immunor‐
eactivity to bacterial antigens. The mucosal immunoglobulin profile of healthy adults consists
predominantly of IgA with only a small amount of IgG. In contrast, patients with active IBD
presented with significantly higher amounts of IgG in their mucosal secretions with no
difference in amounts of IgA as compared to controls. The IgG antibodies present in IBD
patients were identified as binding to non-pathogenic bacterial commensals, including E. coli,
B. fragilis, C. perfringens, Klebsiella aerogenes, and Enterobacter faecalis. Patients with CD had
significantly higher titers than UC patients, while antibody titers to these commensal bacteria
were at or below the limit of detection in serum samples from healthy controls. Notable
differences were also observed in the isotypes of IgG present in UC versus CD patients.
Specifically, UC patients produced predominantly IgG1 and IgG3 antibodies to bacterial
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antigens, while IgG1, IgG2, IgG3 were the predominant isotypes reacting with the bacterial
antigens in serum samples from CD patients [126]. Conversely, other reports have described
an increase in IgG1 antibodies in UC patients and an increased in IgG2 antibodies in CD patients
[127-130]. Additional analyses have determined that IgG antibodies in CD patients are
primarily directed towards bacterial cytoplasmic proteins rather than membrane associated
proteins [126]. Despite the presence of many types of antibodies in both the mucosal secretions
and serum of IBD patients, no direct evidence for their involvement in IBD immunopatho‐
genesis has been reported, indicating that they may simply be a marker for immune respon‐
siveness and/or dysregulation [131].
2.3. Environmental factors affecting IBD
Although  there  are  allelic  differences  in  many  people  with  IBD,  genetics  alone  cannot
completely account for the development of IBD nor the increase in the incidence of IBD
worldwide. Studies of monozygotic twins best highlight this concept, as there are disease
concordance rates  of  only 50 % for  CD and only 20 % for  UC [132,  133].  Of  interest,  a
British study assessing discordant twins with CD found an association with mumps in‐
fection, smoking, and oral contraceptive usage with the development of CD [134]. Addi‐
tionally,  the  twin(s)  with  CD  had  suffered  both  a  medical  illness,  more  episodes  of
gastroenteritis, and spent more time with animals. Smoking is one confounding environ‐
mental factor that is of special interest,  because it  appears to have a protective effect on
UC, but increases the risk of CD [132, 135-137]. Another factor that appears to be protec‐
tive for UC is an appendectomy; its effect on CD is not as evident [138-140]. The equiva‐
lent  procedure  performed  in  mice  has  been  shown  to  ameliorate  colitis  in  both
chemically-induced and genetically-engineered  murine  colitis  models  [141,  142].  Modest
associations between oral  contraceptive use and IBD have been documented,  while  oth‐
ers  have  found  breast-feeding  to  be  protective  against  both  UC  and  CD  [143,  144].  A
meta-analysis performed by investigators in New Zealand identified other potential envi‐
ronmental  factors,  including  being  an  only  child,  using  antibiotics  prior  to  and  during
adolescence (four or more courses in year),  and having a pet in the house during child‐
hood [145]. IBD also tends to occur in extended families as first and second degree rela‐
tives  of  IBD  patients  reported  the  occurrence  of  disease  with  a  significantly  higher
frequency  than  the  general  population  [146].  These  finding  strengthen  the  interconnec‐
tion between genetics, environmental factors, and the incidence of IBD.
2.3.1. Antibiotic usage
Antibiotics  are  used  in  the  treatment  of  IBD to  reduce  microbial  load  and dampen in‐
flammatory immune responses. However, their use prior to disease diagnosis is now be‐
ing  identified  as  a  risk  factor  for  developing  IBD.  A  Danish  study  of  IBD  patients
revealed that antibiotic users were 1.84 times more likely to develop IBD, which correlat‐
ed to  a  12  % increase  in  disease  risk  for  each course  of  antibiotics  taken [147].  Further
analysis  revealed  that  antibiotic  users  were  3.41  times  more  likely  to  develop  CD than
UC, which correlated to an increased risk of 18 % per course of antibiotics used. Specifi‐
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cally,  usage of  penicillin  V and extended spectrum penicillins  were  associated with  the
greatest  disease  risks.  A Swedish  study focused on  the  use  of  antibiotics  from birth  to
age 5, a time when the microbiota and immune response are still developing and/or ma‐
turing,  as  a  risk  factor  for  IBD.  They  reported  an  association  between  a  diagnosis  of
pneumonia,  subsequent  antibiotic  treatment  and  the  onset  of  both  pediatric  and  adult
CD [148].  Another study by Card et al.  revealed a statistically significant association be‐
tween antibiotic usage 2 to 5 years prior to diagnosis of CD in patients from the United
Kingdom  [149].  This  finding  was  confirmed  in  a  Canadian  study,  which  reported  that
the more antibiotics taken within 2 to 5 years of diagnosis, the greater the risk of devel‐
oping  IBD  [150].  That  same  study  found  that  disease  risk  was  weakly  associated  with
penicillin use and greatly associated with metronidazole use,  which was prescribed pri‐
marily for “non-infectious gastroenteritis.” This association with antibiotic usage may be
explained by the failure of the gut microbiota to reestablish its normal community struc‐
ture and function following a course of antibiotics [151].  This alteration in the microbio‐
ta  or  dysbiosis  may  be  a  predisposing  factor  to  the  onset  of  IBD  in  a  susceptible
individual.
2.3.2. MAP
Another  potential  environmental  risk  factor  for  the  development  of  IBD  is  a  chronic
pathogenic infection in the GIT.  To date,  no one particular organism has been found to
be the causative agent of IBD. Although many microbial pathogens have been implicated
as causative,  only two have been significantly investigated.  The first  organism hypothe‐
sized to  be  associated  with  IBD was  Mycobacterium avium  subsp.  paratuberculosis,  which
causes Johne’s disease in cattle [152,  153].  The granulomatous inflammation observed in
CD patients led many early researchers to investigate various types of Mycobacterial  spp.
in  CD pathogenesis  but  confirmation  was  never  achieved (reviewed in  [154]).  The  first
report  of  M. paratuberculosis-like  organisms isolated from patients  with CD in was pub‐
lished 1984. Now known as M. avium  subsp. paratuberculosis  (MAP), there is still no con‐
sensus as to whether or not it plays a role in the onset of IBD in a subset of genetically
susceptible patients [155]. Using PCR to amplify the DNA insertion element IS900, which
is  specific  to MAP, in biopsy sections,  Sanderson et  al.  reported that  65 % of  adult  CD
patients examined were PCR positive [156]. Dell’Isola et al.  reported that 72 % of pedia‐
tric CD patients examined were PCR positive for the presence of MAP [156, 157]. While
many  studies  have  reported  the  presence  of  MAP  DNA  in  CD  patients,  just  as  many
have found MAP DNA in samples from healthy individuals  and UC patients  [156-162].
Moreover,  multiple  studies  have  failed  to  detect  MAP-specific  DNA in  any CD patient
sample  examined [163-169].  The  ability  to  detect  MAP in  some tissue  samples  and not
others  may  be  due,  in  part,  to  the  organism’s  fastidiousness,  slow  growth,  and/or  the
presence of PCR inhibitors in fecal/tissue samples that inhibit  the detection of IS900. Se‐
rological evidence also fails to provide definitive answers for the involvement of MAP in
the  pathogenesis  of  IBD.  Some  studies  assessing  the  presence  of  serum  antibody  titers
against MAP-derived antigens find an association with IBD [170-176] while others do not
[177-182].  More recent  work has identified a possible link between variants in the Nod2
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gene and the  presence  of  MAP [183].  In  this  study,  68  % of  CD patients  were  positive
for MAP DNA based on PCR analysis  as compared to 21 % of  the healthy individuals.
Fifty-one percent of the CD patients were carriers of NOD2 polymorphisms as compared
to 21 % of healthy individuals, and 74 % of the CD patients possessing one of the mutat‐
ed NOD2 alleles were positive for MAP DNA. Even with of all of the data collected, the
debate continues as to whether or not MAP plays an important role in the pathogenesis
of CD [184, 185].
2.3.3. Adherent-invasive Escherichia coli
Another organism implicated in IBD pathogenesis is adherent-invasive Escherichia coli (AIEC).
First described in 1998, AIEC isolates were recovered from the ileal mucosa of CD patients
[186]. These organisms are found in higher numbers in CD patients (22 %) as compared to
healthy controls (6 %) [187]. These isolates were able to adhere to Caco-2 cells and did not
posses any of the virulence genes associated with known E. coli pathotypes (e.g., ETEC, EHEC)
[186]. A characterization of expressed adhesions in AIEC strains revealed the Pap and Sfa
adhesion or colonization factors, both of which are found in uropathogenic E. coli strains;
however many of the AIEC strains did not possess any of the known adhesions associated
with pathogenic E. coli (e.g., intimin). Some of the cytotoxic strains were found to express the
hly operon, and it was subsequently demonstrated that these organisms express a type 1 pili
similar in sequence to an E. coli strain associated with avian colisepticemia and meningitis
[188]. Type 1 pili are involved in both the adherence and internalization of E. coli into host cells.
They specifically bind to the CEACAM6 receptor on ileal enterocytes, which is expressed at
significantly higher levels in the inflamed small intestinal epithelium of CD patients as
compared to healthy controls [189].
Further research involving the prototypic AIEC strain, LF82, has shown that this pathogenic
group of E. coli invades epithelial cells via engagement of actin microtubules and microfila‐
ments and replicates intracellularly even without possessing any of the known invasive
determinants found in other invasive E. coli strains [190]. AIEC strains are also able to survive
and replicate within macrophages without causing apoptosis; they also induce production of
the pro-inflammatory cytokine TNF-α [191]. LF82 is also able to induce in vitro aggregation of
peripheral blood mononuclear cells (PBMCs), an observation reminiscent of the granulomas
observed in the colonic tissue of CD patients [192].
In addition to being detected with increased frequency in human IBD patients, AIEC strains
have also been isolated from Boxer dogs with granulomatous colitis. These E. coli isolates were
found to have the same adherent-invasive phenotype as human AIEC strains. The Boxer dog
isolates were also of the same phylotype (B2 and D) and possessed similar virulence gene
profiles as LF82. In contrast to the human AIEC strains, however, the canine AIEC strains were
only isolated from diseased dogs and not healthy controls. Simpson and colleagues also
demonstrated that remission of colitis in Boxer dogs could be achieved by treatment with
enrofloxacin, the use of which resulted in the eradication of AIEC E. coli [193].
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2.4. The microbiota and IBD
Although no single organism has been implicated in the induction of IBD, a preponderance of
studies indicates that the GI microbial community of IBD patients is different from that of
healthy individuals. This imbalance is known as “dysbiosis”. Characteristics of a dysbiotic
community in IBD include a reduction in members of the C. leptum and C. cocciodes clusters
(members of the Firmicutes phyla and major butyrate producers) and an increase in Entero‐
bacteriaceae and members of the Bacteroidetes, thereby leading to a reduction in the microbial
diversity of the gut. Another notable difference is the greater concentration of mucosally-
associated bacteria in IBD patients as compared to healthy individuals [194-197]. Using
fluorescence in situ hybridization (FISH), patients with CD were found to have predominantly
Enterobacteriaceae, γ-Proteobacteria, or Bacteroides/Prevotella adherent to their mucosa and
present in their submucosa [195]. Another FISH-based analysis revealed that Bacteroides spp.
were the dominant gut bacteria, representing up to 80 % of the total mucosally-adherent
bacterial population in some samples. Of interest was the authors’ additional finding that
treatment of IBD patients with mesalamine (an anti-inflammatory therapeutic drug) signifi‐
cantly reduced the numbers of mucosally-adherent bacteria [198].
Sample origin is an important factor to consider when interpreting data for microbial analyses.
Although stool samples are easy to obtain, it may not accurately reflect the microbial com‐
munity in the cecum and proximal colon of patients [14]. In a comparative study of the
microbial populations detected in cecal versus fecal samples, more anaerobes and Bifidobacte‐
rium spp. were detected in fecal samples using culture-based methods [199]. Molecular probe
hybridization revealed that facultative anaerobes represented by Lactobacillus, Enterococcus,
and E. coli were higher in numbers in cecal contents, yet the number of strict anaerobes
represented by the Bacteroides, C. leptum, and C. coccoides groups were significantly lower in
the cecal contents. Differences in microbial composition have also been observed when
comparing colonic biopsies versus feces [200]. Analysis of feces from Japanese IBD patients
showed that Faecalibacterium spp. were significantly decreased in CD patients, while Bacter‐
oides spp. were significantly increased only in patients with active IBD [201]. Based on the
Shannon diversity index, this study demonstrated that microbial diversity was significantly
reduced in CD patients both during active disease and remission as compared to healthy
individuals.
Several studies have noted a specific decrease in the numbers of C. leptum and C. coccoides
clusters present in colonic contents or feces in IBD patients [18, 197, 202-206]. A reduction in
the C. coccoides group in UC patients and C. leptum in CD patients has been shown using FISH
probes on patient feces [202]. Another study employing a combination of PCR and FISH
analysis of fecal samples found a reduced presence of both C. leptum and C. coccoides clusters
in IBD patients [197]. Additional analyses revealed significant decreases in the concentrations
of the SCFAs (e.g., butyric and propionic acid) in the feces of IBD patients [197]. In other work,
high throughput sequencing demonstrated reduced numbers of Faecalibacterium, Ruminococ‐
caceae, Alistipes, Collinsella, and Roseburia and increased numbers of Enterobacteriaceae in a twin
with ileal CD as compared to the healthy twin [204]. This latter study again emphasizes the
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involvement of the microbiota in the development of IBD in a genetically susceptible host, as
only one of the twins developed disease.
One  specific  member  of  the  C.  leptum  cluster,  Faecalibacterium  prausnitzii,  has  recently
been the subject of many published studies. This organism is a major butyrate producer
that  also possesses some anti-inflammatory properties [59,  207].  A study by Sokol  et  al.
described a reduction of  both C. leptum  and C. coccoides  clusters  in the stool  of  patients
with  active  IBD  along  with  a  skewed  Firmicutes/Bacteroidetes  ratio  [203].  The  authors
specifically identified a reduction in F. prausnitzii  in IBD patients,  confirming results ob‐
tained using biopsy samples from twins analyzed via qPCR [205].  In other work,  dena‐
turing gradient gel electrophoresis (DGGE) analysis of biopsy samples also demonstrated
a  significant  decrease  in  Faecalibacterium  spp.  along  with  increased  levels  of  E.  coli  and
Clostridium spp. in CD patients as compared to healthy individuals [208]. Using fecal cyl‐
inders and 11 different FISH probes to analyze sections GIT tissue specimens, Swidsinski
and colleagues found the presence of F. prausnitzii  to be significantly reduced in CD pa‐
tients [209]. Of special note, analysis of samples from IBD patients given high-dose corti‐
sol  or  infliximab to  reduce  inflammation revealed a  dramatic  increase  (>14  x109)  in  the
levels  of  F.  prausnitzii  within days of  initiating treatment.  This  increase was short-lived,
however, as levels of F. prausnitzii  decreased when the cortisol dose was reduced or the
time  between  infliximab  infusions  was  increased.  Together,  these  data  indicate  that  in‐
flammation plays a major role in shaping the intestinal microbiota.
Work in murine models of colitis also demonstrates that inflammation in the gut, be it
chemically or bacterially induced, causes an increase in Enterobacteriaceae [210]. Colonization
of mice with Citrobacter rodentium resulted in a reduction of the total number of bacteria in the
colon at 7 and 14 days post-infection; this decrease coincided with the highest levels of both
C. rodentium and intestinal inflammation [211]. Further analysis specifically determined that
members of the Cytophaga-Flavobacter-Bacteroides phylum were decreased. Infection with
C. rodentium infection is self-limiting, and the total bacterial levels returned to normal following
pathogen clearance. These changes in the bacterial load were not simply associated with
colonization of a new organism to the microbial community, such as Campylobacter jejuni, an
organism that does not cause intestinal inflammation in immunocompetent CONVR mice
[212], induced no detectable changes in microbial load.
The induction of GIT inflammation in mice via administration of dextran sulfate sodium (DSS)
in the drinking water for seven days was associated with increased numbers of aerobic bacteria,
specifically Entercococcus faecalis [210]. Bacteroidetes were eliminated from the community and
the total number of bacteria was also decreased. A dramatic increase in the numbers of a non-
pathogenic E. coli following DSS treatment was also observed. The authors subsequently
colonized IL-10-/- mice, which spontaneously develop colitis [213], with this non-pathogenic
E. coli. Upon the development of GIT inflammation, the E. coli was able to proliferate to the
same level observed in DSS treated mice, but displacing the Firmicutes phylum instead of the
Bacteroidetes. These results indicate that regardless of the source, GIT inflammation creates a
niche that favors the colonization and expansion of Enterobacteriaceae. Collectively, these data
suggest that the induction of inflammation following the colonization of the GIT by a bacterial
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provocateur along with perturbations of the microbiota together have a deleterious impact on
the microbiota and mucosal homeostasis.
2.5. Canine IBD
In addition to affecting humans, IBD can also occur in dogs as well [214]. As in human IBD,
the interactions between genetics, the mucosal immune system, inflammation, and environ‐
mental factors (ie, diet and imbalances in the intestinal microbiome) all contribute to the
pathogenesis of canine IBD (Figure 6) [215-217].
Figure 6. The etiology for canine IBD involves complex interactions between host genetics, mucosal immunity, and
the enteric microbiota. Therapeutic intervention with diet, antibiotics and immunosuppressive drugs is aimed at re‐
ducing inflammation and dysbiosis.
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Mutations in innate immune receptors in German shepherd dogs (TLR5, NOD2) have been
linked to IBD susceptibility which in the presence of an inappropriate enteric microbiota may
lead to upregulated pro-inflammatory cytokine production (e.g., IL-17, IL-22, TNF-α) and
reduced bacterial clearance, thereby promoting chronic intestinal inflammation [218, 219].
Commensal bacterial antigens are likely to be important in disease pathogenesis because it has
been observed that boxer dogs with granulomatous colitis (GC) show clinical remission
following the eradication of mucosally associated AIEC that share a novel adherent and
invasive pathotype which bears phylogenetic similarity with AIEC strains recovered from
patients with ileal Crohn’s disease [193, 220, 221]. Moreover, genome-wide analysis in affected
boxer dogs has identified disease-associated single nucleotide polymorphisms (SNPs) in a
gene (NCF2) involved with killing intracellular bacteria [222]. Still others have shown that
CD11c+ cells are significantly decreased in the intestines of dogs with IBD suggesting that
chronic mucosal inflammation may involve an imbalance in the intestinal dendritic cell
population leading to aberrant immune activation [223]. Molecular analysis of the intestinal
microbiome in different breeds of dogs with IBD have consistently shown that diseased tissues
are enriched with members of the families Enterobacteriaceae and Clostridiaceae [224, 225]. These
bacteria are believed to contribute to the pathogenesis of GIT inflammatory disease in dogs as
in humans [187, 226]. A recent trial using high throughput 16S rDNA sequencing methods (ie,
454 pyrosequencing) on intestinal biopsies of IBD dogs revealed a dysbiosis in the mucosally-
adherent microbiota with an increase in sequences belonging to Proteobacteria and a decrease
in Bacteroidetes, Fusobacteria, and the Clostridiales [227]. Taken together, these studies
suggest that chronic intestinal inflammation of canine IBD may be due to overly aggressive
adaptive immune responses to enteric bacteria (or fungi) [225] in hosts with genetic defects
that fail to properly regulate microbial killing, mucosal barrier function, or immune responses.
As in human IBD, environmental factors (diet, microbiota imbalances) likely govern the onset
of inflammation or reactivation and modulate genetic susceptibility to disease.
2.5.1. Clinical and diagnostic features
The clinical manifestations of IBD are diverse and are influenced by the organ(s) involved,
presence of active versus inactive disease, and physiologic complications seen with enteric
plasma protein loss and/or micronutrient (cobalamin) deficiency [215, 216, 228, 229]. Canine
IBD is a disease that predominantly affects middle-aged animals. Vomiting and diarrhea are
most commonly observed and are often accompanied by decreased appetite and weight loss.
Gastric and duodenal inflammation is associated with vomiting and small bowel diarrhea
while colonic involvement causes large bowel diarrhea with blood, mucus, and straining. The
clinical course of IBD is generally cyclical and is characterized by spontaneous exacerbations
and remissions. Importantly, the clinical signs of IBD are not disease specific and share
numerous over-lapping features with other canine disorders. A diagnosis of IBD is one of
exclusion and requires careful elimination of IBD mimics [230]. The possible causes for chronic
intestinal inflammation may be excluded through the integration of history, physical findings,
clinicopathological testing, diagnostic imaging, and histopathology of intestinal biopsies. A
baseline CBC, biochemistry profile, urinalysis, and diagnostic imaging are useful in eliminat‐
ing the most common systemic and metabolic disorders (e.g., renal disease, hepatopathy,
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hypoadrenocorticism) causing chronic GI signs in dogs. The measure of clinical disease activity
by means of quantifiable indices is well established in human IBD [231-233].
A canine IBD activity index (CIBDAI) used for assessment of inflammatory activity in dogs
has been recently designed [234]. Similar to other indices, the magnitude of the numerical score
is proportional to the degree of inflammatory activity. This index serves as the principal
measure of response to a therapeutic regimen and may be used to tailor medical therapy for
an individual patient’s needs [235]. Intestinal biopsies are required to confirm histopatholog‐
ical inflammation and to determine the extent of mucosal disease. Diagnostic endoscopy is
preferred since this technique allows for direct assessment of mucosal abnormalities and the
acquisition of targeted biopsy specimens. The microscopic findings in canine IBD consist of
minimal to pronounced inflammatory cell (lymphoplasmacytic) infiltration of the intestinal
lamina propria accompanied by varying degrees of mucosal architectural disruption similar
to that observed in tissue from human IBD patients (Figure 7).
 
Figure 7. Histopathological lesions of (A) crypt distortion with abscessation, (B) diffuse villous atrophy, and (C) mucos‐
al ulceration seen in duodenal biopsies of dogs with IBD.
Unfortunately, biopsy interpretation is notoriously subjective and suffers from extensive intra-
observer variability and the technical constraints of procurement/processing artifacts inherent
in evaluation of endoscopic specimens [236]. Although several histopathological scoring
schemes have been proposed there are no uniform grading criteria that pathologists can
universally agree on. One small study has resulted in development of a ‘simplified model
system’ for defining intestinal inflammation of IBD that is presently being tested in a separate
clinical trial.
2.5.2. Therapeutic approach
Treatment principles for canine IBD are empirical and consist of combination therapy us‐
ing both dietary and pharmacologic interventions. As compared to clinical trials evaluat‐
ing the  efficacy of  therapy for  CD and UC,  only one randomized,  controlled drug trial
for canine IBD has been reported [235]. There are, however, abundant evidence-based ob‐
servations  that  feeding elimination diets  and administering corticosteroids,  immunosup‐
pressive drugs,  and/or select  antibiotics  are useful  in the clinical  management of  canine
IBD.  Some  clinicians  prefer  a  sequential  approach  to  nutritional  and  drug  therapy  for
IBD.  The optimal  drug or  drug combinations  as  well  as  duration of  therapy for  induc‐
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tion and maintenance of  remission of  clinical  signs  have not  been determined for  most
protocols  [216,  230].  In  general,  the  administration  of  corticosteroids  (i.e.,  prednisone,
prednisolone or budesonide), antimicrobials (i.e., metronidazole or tylosin), and immuno‐
suppressive  drugs  (i.e.,  cyclosporine,  chlorambucil,  azathioprine)  used alone or  in  some
combination are effective in inducing clinical remission in most animals. Some dogs will
require intermittent or life-long drug therapy.
The rationale for nutritional therapy of IBD is that restricting exposure to antigens (i.e., dietary
proteins) known to evoke sensitivity will reduce exaggerated host responses and attenuate
intestinal inflammation. Other indications for specialized nutrition include the presence of
decreased appetite, impaired nutrient absorption, or enteric plasma protein loss seen with
moderate-to-severe mucosal inflammation. While evidence-based observations indicate that
most dogs respond favorably to dietary intervention, the superiority of one novel protein
source versus another or the advantage in feeding an intact protein elimination diet versus a
hydrolyzed protein elimination diet has not been shown to date. Modifying the dietary n3:n6
fatty-acid ratio may also modulate inflammatory responses by reducing production of pro-
inflammatory metabolites [237]. There is relatively sparse clinical data investigating prebiotic
or probiotic therapy for canine IBD (see subsequent section on probiotics).
2.5.3. Future directions in canine IBD
Canine IBD represents a common and frustrating GI disorder in veterinary medicine. More
research is needed to unravel the mechanisms responsible for disease development and to
translate these findings directly to human IBD. The primary features of IBD in humans and
animals are remarkably similar (Table 1).
Feature Human IBD Canine IBD
Genetic basis Yes Likely
Etiology Unknown but multifactorial Unknown but multifactorial
Involves the microbiota Yes Yes
Hematochezia Yes Yes
Diarrhea Yes Yes
Definitive Diagnosis GI biopsy GI biopsy
Disease activity assessment Clinical indices, biomarkers (ASCA,
pANCA, CRP, calprotectin)
Clinical indices, biomarkers (pANCA,
CRP, calprotectin ?)
Responsive to anti-inflammatory drugs Yes Yes
Responsive to antibiotics Yes Yes
Spontaneous GI flares Yes Yes
Table 1. Comparative features of IBD in humans and dogs.
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Recent advances in clinical indices, histopathological standards, and the development of
species-specific immunologic reagents and innovative molecular tools have made the dog an
excellent ‘spontaneous’ animal model to study chronic immunologically-mediated intestinal
inflammation. In addition, the dog has higher genomic sequence similarity to that of humans
than do mice, a species traditionally used for comparative disease genetics [238]. However,
clinical manifestations of complex disease in the mouse do not compare to the human form as
closely as they do in the dog. Furthermore, the lifespan of the dog is much shorter than that
of a human; thus, clinical trials aimed at treatment of IBD can be carried out much quicker and
yield results that should have relevant application to human trials [230, 235, 239].
2.6. Treatment for human IBD
Treatments for human IBD patients typically involve the use of anti-inflammatory drugs,
antibiotics, and there is a growing trend of probiotics and prebiotics being studied to determine
their effects on disease activity. When patients fail to respond to treatment, the last and most
drastic treatment option is surgery to resect sections of the inflamed bowel [240]. Most
treatment options are primarily focused on reducing the inflammation associated with IBD.
Some of these drugs also impact the microbiota and those will be discussed below.
2.6.1. Antibiotics
Given the importance of the microbiota in the pathogenesis of IBD, antibiotic therapy may
seem an obvious treatment option. A meta-analysis by Khan et al. in 2011 reviewed random‐
ized controlled trials utilizing antibiotics in the treatment of IBD [241]. Rifamycin derivatives,
ciprofloxacin, and clofazamine all induced remission in CD patients. Rifaximin (a rifamycin
derivative) is effective against both Gram-negative and Gram-positive anaerobes and aerobes;
it is also poorly absorbed after oral administration, resulting in little to no systemic side effects
[242, 243]. Analysis of the effect of the drug using an in vitro continuous culture method with
fecal samples from CD patients revealed increases in beneficial bacteria post-rifaximin
administration [244]. Significant increases in Bifidobacterium spp., the Atopobium cluster, and
F. prausnitzii were noted, as were increases in levels of lactate, acetate, and propionate as
determined by 1H-NMR spectroscopy [244].
Ciprofloxacin is a fluoroquinolone with broad-spectrum antibiotic activity [245]. In addition
to having anti-bacterial properties, this drug has also been shown to have immunomodulatory
properties as well [246]. In a TNBS mouse model of colitis, administration of ciprofloxacin
ameliorated disease as compared to mice given ceftazidime (an antibacterial with a similar
spectrum of activity compared to ciprofloxacin) [245]. Clinically, mice treated with ciproflox‐
acin did not lose weight and had reduced histopathological inflammatory scores associated
with their colons. Ciprofloxacin treated mice also had reduced expression of IL-1β, IL-8, and
TNF-α as measured from colonic homogenates as well as reduced expression of NF-κB. Since
ceftazidime was less effective in ameliorating GIT inflammation, there appears to be additional
benefits (i.e., anti-inflammatory) to the use of ciprofloxacin in addition to its spectrum of
antimicrobial activity.
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Clofazamine has also been documented to significantly affect the rate of remission in CD
patients [241]. This drug, used to treat leprosy, is similar to ciprofloxacin, in that it has both
anti-bacterial and anti-inflammatory properties [247-249]. It is only effective against Gram-
positive organisms, and its effectiveness increases in anaerobic environments [250]. Its effects
on the immune system include increasing the presence of lysosomal enzymes in macrophages
[251] and increasing phagocytosis by macrophages resulting in enhanced uptake and digestion
of immune complexes [252]. Clofazamine has also been shown to inhibit TCR-mediated IL-2
production by T cells, thereby limiting T cell activation, a component of the pathogenesis of
IBD [253].
2.6.2. Corticosteroids
The most commonly used corticosteroids used are prednisolone, methylprednisolone, and
budesonide [254]. These drugs are very effective at inducing remission, however, they are not
without side effects. In a study comparing prednisolone and budesonide, both were found to
be effective at inducing remission [255]. However, patients on budesonide had reduced
evidence of adrenal axis suppression and peripheral leucocyte counts compared to those
treated with prednisolone. These results indicate that budesonide is a safer choice yet it is still
as effective as prednisolone. Corticosteroids are able to prevent NFκB activation [256] as well
as block infiltration of neutrophils, prevent vasodilation and enhanced vascular permeability
and downregulate the production of pro-inflammatory cytokines [254]. Although it is well
established that these corticosteroids have an anti-inflammatory effect, little research has been
conducted on the effects they have on the gut microbiota. A study by Swidsinski et al.,
mentioned previously, indicated that administration of cortisol increased the population of F.
prausnitzii in a dose dependent manner [209].
2.6.3. Immunosuppressive therapy
Drugs such as methotrexate, 6-mercaptopurine (6-MP) and azathioprine (the prodrug of 6-MP)
work by inhibiting the proliferation and activation of lymphocytes and decreasing the
production of pro-inflammatory cytokines [254]. 6-mercaptopurine (6-MP) and azathioprine
are purine antagonists and inhibit cellular metabolism by interfering with DNA replication
[257, 258]. Methotrexate is a folic acid analog that inhibits DNA synthesis and, therefore, has
an anti-proliferative effect [259]. Antibacterial effects, including growth inhibition of MAP,
have also been demonstrated for methotrexate and 6-MP [258].
2.6.4. 5-aminosalicyclic acid (5-ASA)
Sulfasalazine was the first 5-ASA-type drug developed and is a combination of sulfapyridine
(an antimicrobial) and salicyclic acid (an anti-inflammatory) to form a pro-drug. Upon entering
the colon, this pro-drug is cleaved by colonic bacteria into the two separate molecules [260,
261]. Unfortunately, the frequency of gastrointestinal side effects was quite high due to the
sulfapyridine moiety [262, 263]. It was later determined that the active moiety is 5-aminosali‐
cyclic acid (5-ASA, mesalazine) [264]. More recently formulations of this pro-drug have
eliminated the sulfapyridine moiety and replaced it with either a second salicyclic acid moiety
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(disodium azodisalicylate [265]) or an inert carrier (balsalazide [266]) thereby reducing the side
effects.
In addition to being an anti-inflammatory agent [267-270], 5-ASA also affects the gut micro‐
biota. As mentioned previously, patients taking mesalamine had a reduction in mucosa-
adherent bacteria [198, 271]. 5-ASA has also been shown to inhibit the growth of MAP [272]
and Bacteroides spp. [273] and moderately inhibit the growth of C. difficile and C. perfringens in
culture [273]. This drug also effects bacterial gene expression, as Salmonella enterica serovar
Typhimurium incubated with 5-ASA had no change in growth but differentially expressed
110 genes [274]. Those genes characterized were found to be involved in invasion, metabolism,
and antibiotic and stress resistance. In vitro assays revealed attenuation in the invasiveness of
S. enterica serovar Typhimurium towards HeLa cells when pretreated with 5-ASA. These
results indicate that in addition to inhibiting host-mediated inflammation, 5-ASA also has the
potential to affect the intestinal microbiota.
2.6.5. Anti-TNF monoclonal antibodies
The induction of TNF-α is most often a downstream event following the interaction of
phlogistic microbial components with toll-like receptors (TLRs) on host cells. The interest in
TNF-α as a therapeutic target for IBD treatment began when the expression and secretion of
this cytokine was found to be increased in IBD patients [275, 276]. For example, pediatric
patients with either active UC or CD present with elevated levels of TNF-α in their stool [275].
Additionally, the incubation of GIT tissue sections in culture medium has demonstrated that
significantly elevated levels of TNF-α are spontaneously secreted from inflamed tissue of both
UC and CD patients when compared to the amounts produced by non-inflamed tissue and
tissue from otherwise healthy individuals [276]. The predominant cell type producing the TNF-
α has been shown to be the macrophage [276]. Based on the central role TNF-α appears to play
in the pathogenesis of IBD, there was interest in developing a therapeutic approach to control
the harmful effects of this cytokine.
Clinically, the use of monoclonal antibodies to treat IBD patients began with Infliximab, an
IgG1 murine-human chimeric monoclonal antibody specific for TNF-α, which was approved
for human use in 1998 for CD [277, 278]. This monoclonal antibody consists of human constant
regions and murine antigen binding regions [277]. These chimeric antibodies reduce the risk
of immunoreactivity that occurs when murine antibodies are used. In addition to being less
immunoreactive, this chimeric antibody had improved binding and neutralization character‐
istics for TNF-α than that of the original murine antibody [277]. Another monoclonal anti-TNF
antibody, Adalimumab, is a fully humanized IgG1 antibody that avoids the induction of anti-
species IgG that neutralize the effectiveness of the anti-TNF-α reagent [278, 279]. Lastly,
Certolizumab is a monoclonal antibody fragment with a polyethylene glycol moiety (PEGy‐
lated) [278]. Certolizumab lacks the crystallizable fragment (Fc) portion of the immunoglobulin
molecule and is an IgG4 isotype unlike Infliximab and Adalimumab, which are IgG1 antibodies
[278, 280, 281]. In addition, the PEGylation increases the half-life of the antibody thereby
reducing the frequency of administration.
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Anti-TNF-α therapy works via multi-factorial mechanisms. First, it neutralizes TNF-α by
blocking its ability to bind to TNF receptors, thus, inhibiting the pro-inflammatory response.
Second, Anti-TNF-α binds to cell surface bound TNF-α on CD4+ T cells and macrophages,
resulting in both complement- and antibody-dependent cell-mediated cytotoxicity [282]. All
three monoclonal antibodies bind to and neutralize both soluble and membrane forms of TNF-
α [281]. Infliximab and Adalimumab both mediate complement- and antibody-dependent cell-
mediated cytotoxicity; however, Certolizumab only mediates complement-dependent cellular
cytotoxicity as it lacks of an Fc region. Furthermore, Infliximab and Adalimumab induce
apoptosis in peripheral blood lymphocytes and monocytes, as well as cause degranulation and
loss of membrane integrity of PMNs. These activities were not induced with Certolizumab.
Lastly, all three monoclonal antibodies inhibit the production of IL-1β after LPS stimulation
in vitro, suggesting that there is a sequential production of pro-inflammatory cytokines
induced by microbial components. Infliximab and Adalimumab both inhibit T cell prolifera‐
tion in mixed lymphocyte reactions in vitro, again suggesting that anti-TNF-α monoclonal
antibodies ameliorate the inflammation associated with IBD via more than one mode of action
[283]. The impact of these therapies on the microbiota, however, is not well studied. As
previously mentioned, treatment with Infliximab resulted in increased levels of F. prausnitzii
after administration [209]. As mentioned above, it is clear that the host inflammatory response
often negatively impacts (i.e., shapes) the composition of the GIT microbiota, and that
controlling mucosal inflammation benefits the health of the microbiota as well. Otherwise,
there have been no specific studies performed to directly evaluate the role of anti-TNF-α
therapies on the gut microbiota.
2.6.6. Complementary and alternative therapies
An estimated 70 % of IBD patients have reported using complementary and alternative
medicine (CAM) products at some time to treat their symptoms In a Canadian study of IBD
patients, some of the most commonly used CAM treatments included massage therapy,
chiropractic visits, probiotics, herbs, and fish oils [284]. A systematic review of the literature
on the use of herbal medicines reveals some anti-inflammatory benefits associated with the
administration of these herbs to both animals and humans [285]. It should be stressed that
prior to utilizing any herbal remedy, which are potentially biologically active, patients need
to consult their physician. This is especially important because the number two reason patients
using CAM gave as to why they sought these products was that “natural therapy is safe”[286].
Some of the biological properties associated with CAM products include the reduction of pro-
inflammatory cytokines, increased antioxidant production, inhibition of leukotriene B4,
decreased NF-κB activation, and inhibition of platelet activation [285].
Increasing evidence supports a potential therapeutic role for prebiotic and probiotic therapy
in human IBD [287, 288]. If IBD in dogs is indeed driven by loss of tolerance to components of
the intestinal microbiota as it is in humans, then prebiotics and probiotics may also prove
beneficial as primary or adjunct therapies with diet and drugs. Probiotics are living microor‐
ganisms that, upon ingestion in sufficient numbers, impart health benefits beyond those of
inherent basic nutrition [289]. Lactobacilli and Bifidobacterium have been the most commonly
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used human probiotics, but multi-strain cocktails (e.g., VSL#3), E. coli Nissle 1917, and
nonbacterial Saccharomyces boulardii have also been used as probiotics [226]. Probiotic bacteria
have measurable host benefits, including the ability to improve epithelial barrier function,
modulate the mucosal immune system, and alter the intestinal flora [290]. Prebiotics are non-
digestible dietary carbohydrates, such as lactosucrose, fructo-oligosaccharides (FOS), psylli‐
um, bran, which beneficially stimulate the growth and metabolism of endogenous enteric
bacteria upon consumption [291]. Beneficial effects of prebiotics are also associated with the
production of short chain fatty acids (SCFA) due to fermentation by colonic bacteria. Synbiot‐
ics are combinations of probiotics and prebiotics that are an emerging therapeutic modality.
Increasing evidence supports a therapeutic role for probiotics, prebiotics, and synbiotics in
treating gastrointestinal diseases of humans, including infectious diarrhea, H. pylori infection,
irritable bowel syndrome, lactase deficiency, and IBD [84]. A comparison of prebiotic and
probiotic preparations is outlined in Table 2.
2.6.7. Probiotics
VSL#3 is one of the most commonly used probiotic cocktails and contains a very high bacterial
concentration per gram of product characterized by greater number of different bacterial
species as compared to traditional probiotic preparations [292]. This commercially prepared
formulation consists of 450 billion bacteria/g of viable lyophilized bacteria comprised of eight
bacterial strains (Lactobacillus casei, L plantarum, L. bulgaricus, L. acidolphilus, Bifidobacterium
longum, B. breve, B. infantis and Streptococcus thermophiles). While the exact mechanism of action
of VSL#3 is unknown, several studies have demonstrated the effects of VSL#3 on epithelial
barrier function and down regulation of cytokine secretion from immune cells. For example,
Madsen [293] has shown in in vitro studies that epithelial barrier function could be enhanced
by exposure to a soluble factor secreted by VSL#3 bacteria. Moreover, this same study
demonstrated that VSL#3 did not alter the ability of the epithelial cell to activate a mucosal
inflammatory response to a bacterial invasion. Studies with VSL#3 formulations have also been
conducted in several animal models of colitis, inflammatory liver disease, sepsis, and irritable
bowel syndrome (IBS). In models of experimentally-induced colitis, these studies demonstrat‐
ed that VSL#3 normalized gut permeability and barrier function, and that VSL#3 modulated
inflammatory and immune responses [226, 294]. Animal models of sepsis have also demon‐
strated that VSL#3 administration reduced bacterial translocation and significantly attenuated
damage to the liver and intestinal mucosa [295]. The use of VSL#3 as an innovative probiotic
preparation, developed specifically to balance the intestinal microbiota, is supported by
studies in humans with IBD (ulcerative colitis [296], pouchitis) and in other patients with
diverse gastrointestinal disorders, such as IBS [297, 298].
Studies have shown VSL#3 to induce remission of inflammation in 77 % of adult UC patients
with no adverse effects [298] and 56 % of pediatric UC patients [299]. These same pediatric UC
patients had a reduction in disease activity index and sigmoidoscopy scores following VSL#3
treatment. They also had reduced levels of the pro-inflammatory cytokines TNF-α and IFN-
γ following therapy [299]. In vitro analysis of the effects of VSL#3 on Mode-K epithelial cells
revealed that only one of the eight organisms, L. casei, inhibited TNF-induced secretion of the
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pro-inflammatory chemokine IP-10 [300]. The most recent studies with VSL#3 treatment of UC
show increased fecal concentrations of beneficial bacterial species, improved clinical, endo‐
scopic and histopathological scores in most patients, and higher rates of remission compared
to placebo [298]. The most recent studies with VSL#3 treatment of UC show increased fecal
concentrations of beneficial bacterial species, improved clinical, endoscopic and histopatho‐
logical scores in most patients, and higher rates of remission compared to placebo [298]. VSL#3
is available without prescription and can be ordered via the internet or obtained locally at the
pharmacy in the U.S. [301].
Probiotics Prebiotics
Definition Live microorganisms which, given in
adequate amounts confer health benefits to
the host
Non-digestible carbohydrate which stimulate
replication of protective enteric bacteria
when consumed
Examples E. coli Nissle 1917
VSL#3
Lactobacillus species
Bifidobacterium species
Saccharomyces boulardii
Prostora Max®
Forti Flora®
Proviable-DC®
Fructo-oligosaccharide (FOS)
Galacto-oligosaccharide (GOS)
Inulin
Lactulose
Psyllium
Bran
Beet pulp, pumpkin
Resistant starch
Protective Mechanisms Alters microbiota to suppress pathogens
Improved intestinal barrier function
Increased production of antimicrobial peptides
Decreased expression of proinflammatory cytokines
Stimulates replication of beneficial
bacteria (Bifidobacterium)
Enhances production of SCFA
(butyrate)
Improved intestinal barrier function
Decreases proinflammatory cytokines
Table 2. Basic Features of Probiotics and Prebiotics
Recent studies have also shown that dogs with IBD have distinctly different duodenal
microbial communities compared to healthy dogs. Current treatments for IBD include the
administration of nonspecific anti-inflammatory drugs which may confer serious side effects
and do not address the underlying basis for disease, namely, altered microbial composition.
The use of probiotics offers an attractive, physiologic, and non-toxic alternative to shift the
balance to protective species and treat canine IBD. The authors (AEJ) have initiated a clinical
trial to investigate the clinical, microbiologic, and anti-inflammatory effects of probiotic VSL#3
in the treatment of canine IBD. We hypothesize that VSL#3 used as an adjunct to standard
therapy (i.e., elimination diet and prednisone) will induce a beneficial alteration of enteric
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bacteria leading to induction and maintenance of remission in dogs with IBD. A randomized,
controlled clinical trial of eight weeks duration will assess the efficacy of standard therapy in
conjunction with VSL#3 versus standard therapy alone in the management of canine IBD.
There is a need for additional data to be generated to provide proof of efficacy in probiotic
therapy before these agents can be applied to widespread clinical use. These studies will also
provide highly relevant insight into the anti-inflammatory effects of probiotics for treatment
of human and canine IBD.
Another popular probiotic is E. coli Nissle 1917 also known as Mutaflor®. This probiotic has
been shown to be just as effective as mesalazine in achieving and maintaining remission of
inflammation in UC patients [302-304]. It has recently been shown that when E. coli Nissle 1917
is genetically modified to produce the quorum-sensing molecule AI-2, it affected the beneficial
probiotic properties of this organism [305]. Colonization of healthy newborn infants with E.
coli Nissle 1917 has shown that the presence of pathogenic bacteria in the gut was significantly
reduced compared to non-colonized infants [306]. In vitro studies have shown E. coli Nissle
1917 is able to reduce the invasive ability of multiple pathogenic organisms [307], and also to
reduce the adherent and invasive ability of AIEC [308]. E. coli Nissle 1917 was also shown to
either inhibit the growth (49 %) or overgrowth (30 %) of 79 % of uropathogenic organisms
recovered from children with urinary tract infections [309]. Unlike VSL#3, Mutaflor® cannot
be purchased in the U.S. due to its reclassification by the F.D.A. from a “medical food” (which
is what VSL#3 is classified as) to a “biologic” [301, 310].
There are few reports on the use of probiotic bacteria in dogs and cats. Recent in vitro studies
have confirmed the capacity of a lyophilized probiotic cocktail (e.g., three different Lactobacil‐
lus spp strains) to modulate the expression of regulatory versus pro-inflammatory cytokines
in dogs with chronic enteropathies [311]. However, a clinical trial using this same probiotic
cocktail fed to dogs with food-responsive diarrhea failed to induce consistent patterns of
regulatory (e.g., beneficial) cytokine expression in spite of obvious clinical improvement [312].
One commercially-manufactured probiotic (FortiFlora™–Enterococcus faecium SF68, Nestle
Purina) is reported to potentially control diarrhea and enhance immune responses in dogs and
cats. Several recent trials attest to the short-term efficacy of probiotics in treating acute diarrhea
in dogs and cats [313]. The link between the intestinal microbiota and gastrointestinal health
in companion animals is now obvious. Future developments in the pharmabiotic field must
include performance of randomized clinical trials to determine the role of probiotics and
prebiotics in the management of canine chronic enteropathy. One large multicenter trial
investigating the efficacy of VSL#3 in reducing inflammatory activity of canine IBD is presently
underway
2.6.8. Prebiotics
Prebiotics are substances that can be used to promote specific changes in the microbiota.
Administration has been shown to shift the microbiota in healthy adults; for example, in‐
dividuals  who  consume  either  soluble  corn  fiber  or  polydextrose  had  increases  in  F.
prausnitzii and those who consumed the soluble corn fiber had increases in Roseburia spp.
[314].  As mentioned previously,  both of these organisms metabolically produce butyrate
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and F. prausnitzii  also has other anti-inflammatory properties. In animal models, prebiot‐
ics  have been shown to be effective as  well.  The severity of  DSS-induced colitis  in  rats
was attenuated by administering inulin orally as evidenced by a reduction in histopatho‐
logical  scores  and  myeloperioxidase  accumulation  in  the  colons  [315].  In  addition,  the
acidity of the colonic contents increased in rats fed inulin as well as an increase in Lacto‐
bacillus  spp.  in  the  feces.  In  a  multicenter  trial  feeding  UC  patients  germinated  barley
foodstuff  (GBF),  patients  consuming  GBF  had  improved  clinical  activity  index  scores
[316]. GBF has also been shown to be effective in maintaining remission [317] and reduc‐
ing pro-inflammatory cytokine  levels  in  UC patients  [318].  In  CD patients,  dietary sup‐
plementation  with  fructo-oligosaccharide  (FOS)  reduced  their  disease  activity  index,
increased fecal Bifidobacterium spp. levels as well as increased production of IL-10 and ex‐
pression of TLR-2 and TLR-4 from lamina propria dendritic cells [319].
Scientific studies have also investigated the effects of dietary supplementation with prebiotics
on the intestinal microbiota of healthy dogs and cats. In one study, FOS supplemented at 0.75
% dry matter produced qualitative and quantitative changes in the fecal flora of healthy cats
[320]. Compared with samples from cats fed a basal diet, increased numbers of lactobacilli and
Bacteroides spp. and decreased numbers of E. coli were associated with cats fed the FOS
supplemented diet. However, bacteriologic examination of the duodenal juice in these same
cats showed wide variation in the composition of the duodenal microbiota, across sampling
periods, which was not affected by FOS supplementation [321]. Moreover, healthy Beagle dogs
fed a 1 % FOS diet over a three-month trial showed inconsistent fecal excretion of Lactobacil‐
lus spp. and Bifidobacterium spp. [322]. While FOS supplementation has been shown to have
health benefits, these studies demonstrate that FOS does not have an adverse affect on the
microbiota and suggest that it may have positive physiological benefits as seen in humans.
This observation and the lack of significant side effects associated with FOS supplementation
provide evidence that FOS should be considered as an attractive alternative or adjunct therapy
for IBD in dogs and cats.
3. Mouse models of IBD
Many different mouse models have been utilized in IBD research to elucidate the roles that
bacteria, genetics, the immune response, and environment play in the induction and mainte‐
nance of IBD [323]. They fall into two main categories: chemically-induced and genetically-
engineered models. The composition of the microbiota in the various mouse models is also
discussed. Regardless of the strain of mouse employed in chemically-induced or genetically-
engineered models, there are only five options for its microbiota—conventional, specific
pathogen free, restricted, gnotobiotic, or germ-free. Note that the word gnotobiotic (gnostos–
“known” bios –“life”) indicates that all the organisms present, regardless of the numbers of
species, are known and does not apply only to mice that are completely devoid of microbes
(i.e., germfree).
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3.1. Chemically-induced models
3.1.1. DSS
Dextran sulfate sodium (DSS) is formed by the esterification of dextran with chlorosulphonic
acid [324]. Administered ad libtum in the drinking water, this compound causes enterocolitis
in mice with disease severity being dependent on mouse strain, DSS molecular mass, and
sulfur content [325-328]. Within three to seven days after the addition of DSS (1 to 10 % w/v)
to the drinking water, mice exhibit loose stools, weight loss, and occult blood. Upon necropsy
of mice treated with DSS, cecal atrophy and colonic shortening are noted, and histopathological
examination reveals mucosal ulceration, inflammatory infiltrate, and hyperplastic epithelium
in the colonic mucosa. It has also been reported that glandular dropout occurs prior to signs
of inflammation. Although the exact mechanism of action for DSS-induced colitis is currently
not known, it is thought to manifest epithelial toxicity [329, 330]. Other reports indicate that
DSS increases mucosal permeability within three days of administration (before the appear‐
ance of inflammatory infiltrate) [331]. Studies have also shown that DSS is taken up by
macrophages in the colon and mesenteric lymph node and by Kupffer cells in the liver [326,
330]. When macrophages become laden with DSS, they have a reduced ability to perform
normal homeostatic functions such as tissue repair and phagocytosis of bacteria [332]. DSS
was demonstrated to be cytotoxic to Caco-2 cells, binding to their nucleus, causing cell cycle
arrest and reduced production of reactive oxygen species [333].
Microbial populations of the GIT are altered after DSS administration, with the microbiota of
the treated mice having increased numbers of Bacteroidaceae and Clostridium spp. [326]. This
result indicates that the changes to the microbiota may play a contributory role (e.g., reduction
of butyrate production) in the induction of DSS-induced disease. However, DSS induces more
severe colitis and increased mortality in GF mice as compared to their conventional counter‐
parts [334, 335]. GF mice given either 5% or 1% DSS died at days three or 14, respectively, after
the start of DSS administration [335]. Collectively, these studies indicate that the composition
of the microbiota may influence the sensitivity of mice to DSS-induced colitis as well as support
the idea that the resident microbiota affords cytoprotective benefits for the host.
3.1.2. TNBS (2,4,6,-trinitrobenzne sulfonic acid)
TNBS is a haptenating agent that causes a disease similar to CD when mixed with etha‐
nol and administered rectally as an enema. Mice treated with TNBS develop a pan-colitis
with  the  peak  of  clinical  signs,  such  as  diarrhea  and  rectal  prolapse,  occurring  two  to
four weeks post-administration [112].  Microscopically,  transmural  inflammation is  noted
along  with  neutrophil  infiltration,  loss  of  goblet  cells,  edema,  and  granulomas.  T  cells
isolated  from  the  lamina  propria  secrete  elevated  levels  of  IFN-γ  and  IL-2  following
stimulation with anti-CD3 and anti-CD28. However, administration of anti-IL-12 antibod‐
ies after induction of TNBS-induced colitis reduced the disease severity, and treated mice
also showed reduced production of IFN-γ [112]. Further studies have shown that CD4+ T
cells  recovered  from  mice  with  TNBS-induced  colitis  could  induce  mild  colitis  when
adoptively  transferred  into  naive  control  mice;  the  colitic  lesions  were  characterized by
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inflammatory  cell  infiltrate  that  produced  IFN-γ  [336].  In  that  same  study,  researchers
found that feeding mice TNBS-haptenized colonic protein caused the mice to develop or‐
al tolerance. These mice subsequently failed to develop colitis after TNBS administration
or the transfer  of  CD4+  T cells  from mice with TNBS-induced colitis.  T cells  from these
tolerant mice secreted elevated amounts of TGF-β, IL-4, and IL-10 [336].
3.1.3. Oxazolone
Oxazolone is a haptenating agent that causes a disease in mice similar to UC when mixed
with ethanol and administered rectally [337, 338]. SJL/J mice rapidly develop diarrhea and
weight loss that peaks at day two post-administration with a 50 % mortality rate by day
four.  At day two, the distal  half  of  the colon becomes hemorrhagic and edematous and
histologically shows signs of superficial inflammation. There is epithelial cell erosion, gob‐
let cell depletion, edema, and inflammatory cell infiltrate composed of neutrophils and eo‐
sinophils.  This  is  similar  to  what  is  observed  microscopically  in  the  colonic  tissues  of
human UC patients. These mice also develop elevated levels of IL-4 and IL-5, but no IFN-
γ,  indicating  that  oxazolone  induces  a  Th2  response.  Elevated  levels  of  TGF-β  are  also
noted and may play in a role in the induction of disease in only part of the colon. The
model  has  also  been  examined  for  its  role  in  determining  efficacy  of  IBD  treatments.
BALB/c  mice  given  either  5-aminosalicylic  acid  (5-ASA)  or  sodium  prednisolone  phos‐
phate intra-rectally prior to and during induction of oxazolone colitis  had decreased se‐
verity of disease [337]. The disease is self-limiting, and the mice that survive beyond day
four show increased weight gain and are healthy by days 10-12 post-administration.
3.2. Genetically engineered models
3.2.1. IL-10-/-
In 1993, Kuhn et al. discovered that mice deficient in the anti-inflammatory cytokine IL-10
spontaneously develop enterocolitis  [213].  This model has been popular in IBD research
and this genetic deficiency has been crossed onto many different genetic backgrounds of
mouse [339-345]. The availability of different strains has highlighted the role that genetics
plays in enterocolitis, as the severity of disease is strain dependent. The order of severity
from most severe to least severe is as follows: C3Bir > 129 > BALB/c or NOD/Lt > C57BL/
6  or  C57BL/10.  In  addition  to  strain  differences,  development  of  entercolitis  is  also  de‐
pendent on the microbiota, as GF IL-10-/- do not develop enterocolitis and disease is atte‐
nuated  after  administration  of  antibiotics  to  IL-10-/-  mice  harboring  a  conventional
microbiota [346,  347].  The lack of IL-10 does not affect the development of B or T cells,
but  its  absence  does  result  in  a  lack  of  regulatory  T  cells  [213,  348].  Studies  to  under‐
stand the development of disease in these mice have shown that B cells (while present in
high numbers in the lamina propria) are not needed for the initiation of disease, but that
disease is mediated by CD4+ T cells [342, 349]. Transfer studies using RAG2-/- mice as re‐
cipients  have specifically  shown that  naive CD4+  T  cells  are  capable  of  inducing colitis,
and CD45RBlow  CD4+  T cells  from IL-10-/-  mice can induce disease in these RAG2-/-  mice
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[348,  349].  This  latter  observation implicates  IL-10 as  a  central  mediator  of  regulatory T
cells (CD25+ Foxp3+ CD4+ T cells). It has also been shown that IL-12 and IFN-γ are need‐
ed for initiation but not the continuation of colitis [342, 350]. The increase in the produc‐
tion  of  IL-12  and  IFN-γ  along  with  undetectable  levels  of  IL-4  indicates  that  the
enterocolitis  in  these  mice  is  mediated  by  a  Th1  immune  response,  similar  to  that  ob‐
served in humans with IBD [342, 346].
3.2.2. Mdr1a-/-
In 1994, mice lacking the gene mdr1a were generated. This gene encodes a P-glycoprotein,
which is a drug efflux pump, thus protecting host cells from the build-up of toxic compounds.
It was noted later that these mice spontaneously develop a colitis similar to human IBD and
that disease can be exacerbated by colonization with Helicobacter bilis [351, 352]. These mdr1a-/-
mice have reduced growth rates compared to their WT counterparts and their histological
lesions begin in the proximal colon and proceed distally as disease severity progresses. Mdr1a-/-
males are more susceptible to the onset of severe disease than females [353, 354]. Mdr1a-/- mice
also have increased epithelial permeability and reduced phosphorylation of both occludin and
ZO-1, tight junction proteins, compared to WT counterparts [354]. They exhibit increased
bacterial translocation with bacteria detected in both the spleen and lymph nodes that
correlates with disease severity. Therefore, the induction of disease is associated with a defect
in the epithelial barrier function of the GI tract. In addition to the similar disease progression
found in IBD patients, studying these mice are of interest because the human MDR1 gene has
been mapped on a loci that that is associated with susceptibility of IBD, although this rela‐
tionship is under debate [355-358].
3.2.3. TRUC
TRUC mice are both T-bet-/- and RAG-/- and spontaneously develop colitis by four weeks of
age [359, 360]. T-bet (T-box expressed in T cells) is a transcription factor that aids in the
development of a Th1 response [359]. These mice have increased permeability of their colonic
epithelium that increases with age and increased rate of epithelial cell death. Microscopically,
there is inflammatory cell infiltrate, goblet cell dropout, crypt loss, and the presences of ulcers.
The only cytokine elevated in these mice is TNF-α and disease can be ameliorated using an
anti-TNF-α antibody. The microbiota also contributes to disease in this model, as treatment
with antibiotics was able to “cure” the mice of their colitis. Additionally, the TRUC colitic
microbiota can be horizontally transferred to both WT and RAG-/- mice, and 16S rRNA analysis
of feces from TRUC mice revealed that the presence of Klebsiella pneumoniae and Proteus
mirabilis correlate with colitis. Interestingly, GF TRUC mice colonized with these two organ‐
isms alone do not develop colitis unless a more complete microbiota is present [361].
3.3. CD45RBhi CD4+ T-cell transfer model
C.B.-17 scid mice administered CD45RBhi CD4+ T cells develop a wasting disease which is
not  seen if  CD45RBlo  CD4+  T  cells  or  CD45RBhi  CD8+  T  cells  are  adoptively  transferred
[362-364].  Disease  occurs  three  to  five  weeks  post-administration  and  is  limited  to  the
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large intestine. The mucosa, submucosa, and muscularis all presented with inflammatory
cell  infiltrates (macrophages and CD4+  T cells predominately),  and there was also a loss
of goblet cells, epithelial cell hyperplasia, and deep fissure ulcers. Elevated levels of IFN-
γ were present in these mice, and treatment with anti-IFN-γ or anti-TNF (α and β) anti‐
bodies ameliorated disease in these mice. However, the protection garnered by using the
antibodies was not as great as when CD45RBlo  CD4+  T cells were transferred along with
CD45RBhi CD4+ T cells [362]. This disease type mimics CD with respect to the type of in‐
flammatory  response  generated  (Th1)  and  the  type  of  intestinal  inflammation  present
(transmural infiltrate of CD4+  T cells) [365]. There is also a definite microbial component
in this  model  of  disease,  as  restricted microbiota mice have less  severe disease as  com‐
pared to their SPF counterparts [364].
3.4. Bacterial-induced models
3.4.1. Helicobacter spp.
Although not considered a microbial cause of IBD, the presence of Helicobacter spp. does
adjuvant or predispose mice to the onset of colitis in some models. In our lab, we utilize a dual
hit model of colitis consisting of both Helicobacter bilis colonization and low-dose (1.5%) DSS
to elicit colitis, as shown in Figure 8 [366].
Figure 8. To increase sensitivity to a colitic insult, ASF-bearing C3H/HeN:Tac mice were colonized with a bacterial pro‐
vocateur, Helicobater bilis. An otherwise non-colitic low dose of DSS is then administered resulting in colitis.
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Figure 9. Mice colonized with Helicobacter bilis and subsequently administered a low dose of DSS exhibit colitis that is
not seen with H. bilis or DSS alone. Disease is characterized grossly by colonic shortening, edema, cecal atrophy, en‐
larged lymphoid aggregates, and blood present in the contents. Microscopically, the disease presents with inflamma‐
tory cell infiltrate, crypt hyperplasia, glandular dropout, and cellular erosion
It has been noted that colonization of mice with H. bilis alone can change mucosal gene
expression and alter the immune response in C3H/HeN mice bearing the altered Schaedler’s
flora (ASF) [366, 369]. Genes involved in T cell receptor signaling, the survival and activation
of peripheral B cells, and chemotaxis are a few examples of the host genes that were upregu‐
lated by H. bilis colonization. Genes that were down regulated were involved in fatty acid
metabolism and detoxification. After H. bilis colonization, serum antibodies directed at
antigens derived from members of the ASF are induced [366, 369]. H. hepaticus colonization of
A/JCr mice also induced changes in gene expression in the cecum, with female mice being
more susceptible to the onset of disease [370, 371].
It appears that an over zealous host response to the introduction of the novel organism (i.e.,
provocateur) predisposes certain strains of mice for the onset of typholocoltiis following a
secondary colitic insult. In a study comparing A/JCr mice (that develop mild inflammation) to
C57BL/6 (who do not develop inflammation) mice, cecal gene expression profiles revealed that
A/JCr mice had more genes differentially regulated (176) compared to C57BL/6 (80). Differ‐
entially expressed genes were predominantly those associated with immune response,
chemotaxis, signal transduction, and antigen processing in the A/JCr mice while the genes
upregulated in the C57BL/6 mice were predominately associated with immunoglobulin
production.
In the mdr1a-/- mouse, it is not simply the presence of Helicobacter that results in the induction
of colitis but the specific species of Helicobacter influences the induction of a differential
immune response. In mdr1a-/- mice, H. bilis colonization causes colitis as early as three weeks
post-infection, whereas H. hepaticus colonization ameliorated the severity of colitis in these
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mice compared to the uninfected control mdr1a-/- mice [352]. The disease phenotypes between
spontaneous versus Helicobacter-induced colitis in mdr1a-/- mice were different, with epithelial
ulceration not present in the Helicobacter-induced colitis. When mdr1a-/- mice were co-colonized
with both Helicobacter species, the morbidity and mortality rate was between that of mice
colonized by either H. bilis or H. hepaticus and the colitis that developed was characterized by
dysplasia [372]. H. bilis was also able to out compete H. hepaticus in vivo as evidenced by
recovery of higher numbers of H. bilis, suggesting that these two species may compete for
similar niches in the GIT.
Additionally, colonization of IL-10-/- C57BL/6 mice with Helicobacter species results in the
induction of colitis in otherwise disease-free mice [373]. It was also shown that the onset and
severity of colitis was species specific in relation to colonization by H. bilis or H. hepaticus [374].
With respect to C3Bir.129 IL-10-/- mice, the presence of Helicobacter spp. is required for the
spontaneous onset of disease [339]. Further studies show that colonization of RAG1-/- mice
with Helicobacter species fails to elicit clinical signs of disease after nine months of colonization
and only very mild colonic inflammation was detected at necropsy [374]. Taken together, these
observations indicate that disease induction can be mediated by an aberrant adaptive immune
response initiated by bacterial provocateurs entering an otherwise stable host-microbe
environment.
3.4.2. Brachyspira hyodysenteriae
Similar to the need for the a resident microbiota in the TRUC model of colitis, mice colonized
with Brachyspira hyodysenteriae also require the presence of a microbiota for the induction of
typhlocolitis. B. hyodysenteriae is an anaerobic spirochete that is the causative agent of swine
dysentery [375]. While the pathogenesis of B. hyodysenteriae is associated with the production
of a ß-hemolysin [376], disease does not develop in the absence of a resident microbiota as was
demonstrated by the inoculation of germfree pigs [377-379]. The importance of the microbiota
was further demonstrated when the microbiota of C3H/HeSnJ or BALB/c mice was depleted
by adding a cocktail of antibiotics (rifampicin, colistin, spectinomycin, spiramycin, and
vancomycin) to their drinking water. As can be seen in Figure 10, the antibiotic cocktail
depleted the numbers of Gram-positive, Gram-negative, and strict anaerobes by as much as 5
to 7 log10 (Nibbelink and Wannemuehler, unpublished observations). On day seven, antibiotic
treated and sham treated mice were inoculated with 1 x 108 B. hyodysenteirae strain B204 and
severity of disease was evaluated at 5, 10, and 15 days post-infection (DPI). As can be seen in
Figure 11, the sham-treated mice developed severe typhlocolitis while the antibiotic treated
mice had no lesions. At 15 DPI, the antibiotics were withdrawn from the drinking water of the
remaining B. hyodysenteriae-infected mice to allow the microbiota to recover. On day 30 PI, the
mice that had been treated with antibiotics through 15 DPI now presented with severe
typhlocolitis. The presence and severity of typhlocolitis in these mice correlated with the
presence of TNF-specific mRNA in the cecal tissue of the B. hyodysenteriae-infected mice (data
not shown). Lastly, B. hyodysenteriae-induced typhlocolitis could also be prevented when the
host’s inflammatory response was inhibited [380, 381]. Collectively, these observations
indicate that certain bacterial provocateurs (K. pneumoniae, P. mirabilis, and B. hyodysenteriae)
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may fail to induce disease in the absence of an appropriate resident microbiota. As depicted
in Figure 12, the etiology of colitis is complex and may require the presence of a microbial
provocateur, the resident microbiota, and a host inflammatory response.
Figure 10. To assess the role of the microbiota in Brachyspira hyodysenteriae-induced typhlocolitis, C3H/HeSnJ mice
were treated with an antibiotic cocktail to deplete the resident microbiota. Six days later, mice were infected with B.
hyodysenteriae. The data indicate that there was a five to seven log10 reduction in the resident microbiota.
3.5. Conventional mice
The majority of commercially available mice harbor a “conventional” microbiota. This simply
means that the composition of the community is unknown. There are different types of
conventionally-reared mice. For example, Taconic Farms maintain two types of conventional
microbiota mice, restricted flora™ (RF) and murine pathogen free™ (PF). RF mice are not
colonized by β-hemolytic Streptococcus species, K. pneumoniae, K. oxytoca, Pseudomonas aerugi‐
nosa, or Staphylococcus aureus. Mice that are PF are Helicobacter free but can contain organisms
not found in RF mice [382]. Additionally, mice on the same background purchased from
different vendors can harbor different microbiota, as highlighted in work by Ivanov and
colleagues demonstrating the presence of SFB in C57BL/6 mice from Taconic but not Jackson
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Laboratories [54]. This lack of consistency in microbiota from mice of the same strain has even
been identified at different facilities from the same vendor (Overstreet and Wannemuehler
unpublished observation). Therefore, comparison of studies evaluating the microbiota of mice
are difficult because there are hundreds of unknown bacterial species present in the murine
microbiota and there is no standardized microbiota used by investigators. The advent of next-
gen sequencing has helped to alleviate some of this challenge as all of the organisms in the gut
can be identified based on 16S rRNA sequences. However, it still does not resolve the issue
related to the use of disparate strains of mice with varying microbiota from different suppliers.
Figure 11. Assessment of Brachyspira hyodysenteriae-induced typhlocolitis in C3H/HeSnJ mice treated with an antibi‐
otic cocktail. While B. hyodysenteriae colonized the antibiotic-treated mice to the same extent as it did the sham-treat‐
ed mice, there was no evidence of typhlocolitis in the antibiotic treated mice through 15 days post-infection (DPI).
However, 15 days after the antibiotics were withdrawn (30 DPI), the mice that had been treated with the antibiotics
had developed severe disease once the microbiota recovered.
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Figure 12. The pathogenesis of inflammatory bowel disease is complex. Studies from animal models indicate that the
etiology of disease involves the presence of a bacterial provocateur, the resident microbiota, and the host response.
3.6. Germfree mice
GF  mice  are  completely  devoid  of  microbial  life.  As  mentioned  previously,  this  does
grossly affect  the anatomy of  these mice,  which is  most  evident by the enlarged cecum
being the most  prominent  feature  [34].  The discovery that  many GF mouse strains  that
carry genetic deficiencies associated with IBD (notably the IL-10-/-) do not develop colitis
has led to the popularity of GF models to study the role of bacteria in the pathogenesis
of  IBD  [346].  To  determine  if  an  organism  is  capable  of  initiating  colitis,  GF  mice  are
monoassociated  with  a  single  bacterial  species  and then  monitored  for  clinical  signs  of
disease. Some of the bacterial strains used to date to evaluate their ability to induce dis‐
ease in IL-10-/- mice are shown in Table 3.
Organism Colitis Severity Time of Disease Onset Reference
Enterococcus faecalis Severe 10-12 weeks p.i. [383, 384]
Escherichia coli (from WT SPF mouse) Moderate 3 weeks p.i. [383]
Pseudomonas flourescens No disease - [383]
Helicobacter hepaticus No disease - [385]
Lactococcus lactis No disease - [384]
Viridans group Streptococcus No disease - [386]
Clostridium sordellii No disease - [386]
Bacteroides vulgatus No disease - [386]
Bifidobacterium animalis Mild 23 weeks p.i. [387]
Bifidobacterium infantis No disease - [387]
Table 3. Bacterial strains used to monoassociate GF mice to examine the ability of the strain to induce colitis
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Although the information gathered from these studies  has been useful  in  analyzing the
immune response to specific organisms, trying to relate the resultant disease to that char‐
acteristic of IBD is marginal at best because of the differences in the complexities of the
microbiota.  IBD itself  is  a  multi-factorial  disease  and it  has  been  fairly  well-established
that  the  role  of  bacteria  in  IBD is  associated  with  a  shift  in  community  dynamics  (i.e.,
dysbiosis)  and not  the  presence/absence of  one particular  species.  A perfect  example of
this  complexity is  the fact  that  K. pneumonia  and P.  mirabilis  fail  to  induce colitis  in GF
TRUC mice (Figure 12) [361].
3.7. Defined microbiota mice
Also referred to as gnotobiotic, defined microbiota (DM) mice have a microbiota in which all
members are known and are housed in flexible film isolators to maintain this status [388]. One
of the most established DM mouse models harbors the “Altered Schaedler Flora” (ASF).
Developed by Dr. Rodger Orcutt and colleagues as a request from the National Cancer
Institute, these eight microbial species were originally used to standardized the microbiota of
the rodents used as founders in their breeding colonies [389]. He chose to modify his mentor’s
(Dr. Russ Schaedler) cocktail of organisms by eliminating facultative anaerobes (Escherichia
coli var. mutabilis and Streptococcus fecalis) and the anaerobic Streptococcus and Clostridia spp.
that formed the original “Schaedler Flora”. Dr. Orcutt added four additional species (see Table
4 below). This resulted in an anaerobic community devoid of any cocci or spore-forming blunt
ended rods, which comprise the main isolator contaminants, making it easier to monitor for
contamination of the gnotobiotic isolator. This new community was dubbed the “Altered
Schaedler Flora” and was utilized in the breeding stock by major commercial mouse vendors
in the US in that era. The ASF consists of members with different morphologies so that
identification using fecal smears for microscopic evaluation was possible. The members, whose
full genomes have yet to be sequenced, have had 16S rRNA sequencing performed to assist
with the identification of the organisms [390].
Multiple studies have demonstrated the stability of this community both when maintained
under gnotobiotic housing conditions or when part of a conventionalized microbiota [391-394].
In our own lab, all eight ASF members have been stably maintained in our breeding colony
for over 12 years, indicating the remarkable stability of this model microbial community over
time. PCR primers have been developed for each of the eight ASF members as well as group-
specific FISH probes [391, 394]. Therefore, the effects of any perturbation of the ASF, such as
with antibiotics, inflammation, or CAM treatments can be monitored by bacterial abundance
as well as spatial redistribution using qPCR and FISH, respectively. All of the organisms can
be cultured and whole cell sonicates produced to measure the immune response to each
organism individually (something that is impossible to do with a conventional microbiota).
Additionally, this community, although limited in scope, is able to synthesize all the metabo‐
lites needed by the mouse and maintains near normal cecal shape and size, something not
possible in GF mice. It is important to note, however, that some of the characteristics of ASF
mice are more similar to GF than conventional mice. Both ASF and GF mice have high fecal
tryptic activity and possess the ability to degrade mucin and β-aspartylglycine. They also
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cannot convert bilirubin to urobilinogens or cholesterol to coprostanol [395]. Interestingly, this
same research team compared these parameters in CD patients versus healthy subjects and
the characteristics of the microbial metabolism associated with the microbiota of CD patients
were very similar to those of the ASF [396]. This study suggests that there is benefit to the use
of the ASF in mouse models of IBD.
Other defined microbiota mouse studies have been published [397-400]. A study using ten
bacterial species specifically chosen for their metabolic function were used to colonize GF mice
[397]. Using microbial RNA-seq, the authors were able to build a model relating perturbation
of the microbial community to changes in diet. By modeling the functional capacity of a
gnotobiotic community under different conditions, this model and similar approaches can be
used to unravel the operational dynamics of the gut microbiome with respect to nutrient
utilization such that the microbiota might be manipulated to improve human and animal
health [397]. Another study colonized mice with E. rectale and B. thetaiotamicron, and the
authors then assessed changes in bacterial gene expression using Affymetrix GeneChips to
show that the cross-talk between these two organisms affected up- and down-regulated genes
in response to one another.
Strain Identity
ASF356 Most closely related to Clostridium propionicum (92% max identity) [390]
Member of Clostridium cluster XIV
ASF360 Lactobacillus intestinalis (99% max identity) [401]
ASF361 Lactobacillus murinus [390]
ASF457 Mucispirillum schaedleri [402]
ASF492 Eubacterium plexicaudatum [403]
Member of Clostridium cluster XIV
ASF500 Clostridium sp. with no known related organism in GenBank Database [390]
ASF502 Most closely related to Ruminococcus gnavus (92% max identity) [390]
Member of Clostridium cluster XIV
ASF519 Parabacteroides goldsteinii (99% max identity) [404, 405]
Table 4. Members of the altered Schaedler flora
Three human commensals, E. coli, B. longum, and L. johnsonii, have also been used to colonize
GF mice to create a gnotobiotic community [398]. This community was used to identify the
effects that the introduction of novel organisms has on the community dynamic. When
colonized with a second Lactobacillus, L. paracasei, it was noted that both Lactobacillus spp. were
able to co-habitate reaching similar fecal titers. However, that was not the same when a fifth
organism was added, a second B. longum strain. This new strain was only maintained in the
mouse at detectable levels for three days. Lastly, a second E. coli strain was added to the original
community of three. This new E. coli reached the highest titer of any organism in the com‐
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munity. This addition caused the reduction of the original E. coli to drop to undetectable levels
at day two post-addition. Later L. johnsonii also reached undetectable levels. B. longum
decreased initially but them returned to normal titer levels. Lastly, when the original tri-
associated mice were exposed to conventional mouse feces, the numbers of the original three
organisms decreased.
In this chapter, we have discussed the three most common types of microbiota available for
use in IBD research. Because it is clear that IBD is associated with an imbalance in the microbial
community, the use of GF mice (which cannot mimic a “community” dynamic) may be less
useful in unraveling the complexities of a multifactorial disease in place of defined microbiota
and conventional microbiota mice. Ideally, one would want to use a simplified community
(such as the ASF) where the actions of all organisms can be assessed. To understand the
dynamic interactions that occur between microbes and between the microbes and the host, it
will be important to start with what is known in order to begin the unraveling the enigmatic
nature of gut health and disease.
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